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To monitor inflammation in a meaningful way, the markers used must be valid: they must reflect the inflammatory process under study and
they must be predictive of future health status. In 2009, the Nutrition and Immunity Task Force of the International Life Sciences Institute,
European Branch, organized an expert group to attempt to identify robust and predictive markers, or patterns or clusters of markers, which
can be used to assess inflammation in human nutrition studies in the general population. Inflammation is a normal process and there are a
number of cells and mediators involved. These markers are involved in, or are produced as a result of, the inflammatory process irrespec-
tive of its trigger and its location and are common to all inflammatory situations. Currently, there is no consensus as to which markers of
inflammation best represent low-grade inflammation or differentiate between acute and chronic inflammation or between the various
phases of inflammatory responses. There are a number of modifying factors that affect the concentration of an inflammatory marker at
a given time, including age, diet and body fatness, among others. Measuring the concentration of inflammatory markers in the bloodstream
under basal conditions is probably less informative compared with data related to the concentration change in response to a challenge.
A number of inflammatory challenges have been described. However, many of these challenges are poorly standardised. Patterns and clus-
ters may be important as robust biomarkers of inflammation. Therefore, it is likely that a combination of multiple inflammatory markers and
integrated readouts based upon kinetic analysis following defined challenges will be the most informative biomarker of inflammation.
The overall aim of the present study is to attempt to identify
robust and predictive markers, or patterns or clusters of mar-
kers, which can be used to assess inflammation in human
nutrition studies in the general population. Inflammation is a
normal component of host defence, initiating the mechanisms
involved in pathogen killing and protection against other
insults. Thus, in a physiological context, inflammation is pro-
tective. Typically, the inflammatory response is activated
rapidly in response to infection or another trigger and then
follows a temporal pattern of cellular activation and chemical
mediator release. Once the infection or the other insult is
eliminated, or at least controlled, mechanisms come into
play to terminate inflammation in order to limit further
damage to the host and to initiate tissue repair. This process
is termed resolution of inflammation, and it is now recognised
to be an active process involving specific mediators that act to
down-regulate the processes that were earlier activated. Fail-
ure to resolve inflammation may permit the normally acute
inflammatory processes to become chronic. Chronic inflam-
mation may also be driven by continuous exposure to the
triggering agent. Chronic inflammation is a well-recognised
component of many pathologies and is a target for many phar-
macologic interventions. In order to examine the role of diet,
foods or specific nutrients on inflammation, it is necessary to
identify candidate biomarkers. This review describes a sys-
tematic approach to identify generic biomarkers of inflam-
mation and to consider the factors that may influence the
status of those biomarkers.
Biomarkers of inflammation
Inflammation: a general overview
Inflammation is a normal host defence mechanism that pro-
tects the host from infection and other insults; it initiates
pathogen killing, as well as tissue repair processes, and
helps to restore homeostasis at infected or damaged sites(1).
A number of different triggers can initiate inflammation.
These triggers include the presence of microbial products,
tissue damage and metabolic stress (Fig. 1). Exposure to the
trigger may involve a breakdown in barrier function or a
loss of normal immune tolerance. Irrespective of the nature
of the trigger, a common set of cellular pathways is initiated(2).
These pathways include activation of signalling via Toll-like
receptors and nuclear factor (NF)-kB, formation of a multi-
protein complex termed the inflammasome that is responsible
for the release of several inflammatory cytokines, and endo-
plasmic reticulum (ER) stress (Fig. 1)(2). The resulting inflam-
matory response is typified by redness, swelling, heat, pain
and loss of function, and involves interactions among many
cell types and the production of, and responses to, a vast
number of chemical mediators. The precise timing and
vigour of the inflammatory response, including the exact
cells and mediators involved, is determined by the nature,
extent and location of the trigger. These factors act to shape
and maintain the inflammatory response. Once the infection
or the other trigger is eliminated, or at least controlled, mech-
anisms come into play to terminate inflammation in order to
limit further damage to the host and to initiate tissue repair.
This self-regulating process is termed resolution of inflam-
mation and involves the activation of negative feedback mech-
anisms such as the secretion of anti-inflammatory cytokines,
the inhibition of pro-inflammatory signalling cascades, the
shedding of receptors for inflammatory mediators and the acti-
vation of regulatory cells. Properly controlled inflammation is
essential to remain healthy and maintain homeostasis, but
inflammation that involves a loss of tolerance or regulatory
processes may become pathological(1).
Inflammation may be classified as acute or chronic (Table 1).
Acute inflammation is the initial response of the body to an
infectious agent or another inflammatory trigger (e.g. tissue
damage by wounding or irradiation) and is achieved by the
increased movement of plasma and leucocytes (especially
granulocytes) from the blood into the site of infection or
injury. A cascade of biochemical events matures and propa-
gates the inflammatory response, involving the local vascular
system, the immune system and various cells within the
injured tissue. Acute inflammation is typically self-limiting
with resolution being activated once the cause of the initial
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response is contained or eliminated. Resolution is itself
an active process involving specific cell types and specific
anti-inflammatory cytokines(3) and pro-resolving lipid
mediators(4,5). Prolonged, or chronic, inflammation involves
a progressive shift in the type of cells present at the site of
inflammation and simultaneous destruction and healing of
the tissue due to the ongoing inflammatory process. Inflam-
mation may become pathological due to the loss of tolerance
and/or of regulatory processes such as resolution. Where this
becomes excessive, irreparable damage to host tissues and
disease can occur(1). Such diseases are characterised by mark-
edly elevated concentrations of inflammatory markers and of
activated inflammatory cells at the site of tissue damage and
in the systemic circulation; this state of inflammation may be
regarded as ‘high grade’. These diseases include rheumatoid
arthritis (RA), inflammatory bowel diseases (IBD), atopic der-
matitis, psoriasis and asthma. Chronic inflammation can also
be of a ‘low grade’ and under such circumstances, overt clini-
cal manifestations can be minimal or absent; the elevation in
the concentrations of inflammatory markers and of inflamma-
tory cells in the systemic circulation is not as great as that seen
in the frank chronic inflammatory conditions described above.
Low-grade asymptomatic inflammation can occur in adipose
tissue as a feature of obesity(6). Under these conditions,
the adipocyte itself becomes the source of inflammation-
associated adipokines, although there is also infiltration of
adipose tissue by macrophages and T cells, which make
important contributions to the inflammatory output from adi-
pose tissue(7). The cytokines and adipokines released prob-
ably contribute to the insulin resistance seen in obesity(8).
Older people also commonly exhibit low-grade chronic
inflammation that may contribute to frailty, depending on
the plasma levels of factors such as tumor necrosis factor
(TNF) and interleukin (IL)-6.
Common to both acute and chronic inflammation is that
they have an afferent phase, in which the presence of a trigger
is sensed by some types of cells, and an efferent phase, in
which an inflammatory response is generated to eliminate
the perceived hostile intruder (i.e. the source of the trigger).
Irrespective of the type of inflammation, the response involves
four major events. The first event is increased blood supply to
the site of inflammation. The second event is increased capil-
lary permeability caused by retraction of endothelial cells. This
permits larger molecules, not normally capable of traversing
the endothelium, to do so and thus delivers some soluble
mediators to the site of inflammation. The third event is
leucocyte migration from the capillaries into the surrounding
tissue (Fig. 2). This is promoted by the release of chemo-
attractants from the site of inflammation and by the
up-regulation of adhesion molecules on the endothelium.
Once in the tissue, the leucocytes move to the site of
inflammation. The fourth event is the release of mediators
from leucocytes at the site of inflammation. These may include
lipid mediators (e.g. prostaglandins (PG), leukotrienes; see
Table 2), peptide mediators (e.g. cytokines, chemokines;
see Table 3), reactive oxygen species (e.g. superoxide),
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Fig. 1. Schematic overview of the common inflammatory response initiated by different triggers. Triggers are those factors that can directly initiate an inflammatory
response. ER, endoplasmic reticulum; TLR, Toll-like receptor; TNFR, TNF receptor.
Table 1. Features of acute, chronic and low-grade chronic inflammation
Acute inflammation Chronic inflammation Low-grade chronic inflammation
Trigger Pathogens, injured tissues Failure to resolve acute inflammation due
to non-degradable pathogens, persistent
foreign bodies or autoimmune reactions
Metabolic disturbance; some chronic
infections
Major cells
involved
Neutrophils and other granulocytes,
mononuclear cells (monocytes,
macrophages); T cells later
Mononuclear cells (monocytes, macro-
phages, T cells, B cells), neutrophils,
fibroblasts
Mononuclear cells (monocytes, macrophages,
T cells, B cells), neutrophils, adipocytes
(if adipose tissue involved)
Primary
mediators
Vasoactive amines, eicosanoids;
chemokines and cytokines later
Cytokines, chemokines, eicosanoids,
growth factors, reactive oxygen species,
hydrolytic enzymes
Cytokines, chemokines, adipokines
(if adipose tissue involved), eicosanoids,
reactive oxygen species, hydrolytic enzymes
Onset Immediate Delayed Delayed
Duration A few days Unlimited Unlimited
Outcomes Resolution, abscess formation,
chronic inflammation
Tissue destruction, fibrosis, necrosis No overt pathology, tissue (vascular) damage,
increased insulin resistance, intracellular
lipid accumulation
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amino acid derivatives (e.g. histamine) and enzymes (e.g.
matrix proteases), depending upon the cell type involved,
the nature of the inflammatory trigger, the anatomical site
involved and the stage during the inflammatory response.
Several of the mediators involved act to amplify the inflam-
matory process by acting, for example, as chemoattractants.
Some of the inflammatory mediators escape the inflammatory
site into the circulation and from there, they can exert systemic
effects (Fig. 2). For example, the cytokine IL-6 released into
the bloodstream from an inflammatory locus induces hepatic
synthesis of the acute-phase protein C-reactive protein
(CRP), while the cytokine TNF elicits metabolic effects
within skeletal muscle, adipose tissue and bone. Thus, inflam-
mation at one site, such as within the intestinal mucosa,
can cause inflammation-driven changes at distal sites, such
as in bone.
The need to identify biomarkers of inflammation
Inflammation has long been recognised to play a key role in
the pathology of a number of human diseases, including RA,
psoriasis, Crohn’s disease, allergic asthma and atopic dermati-
tis, being centrally involved in the tissue damage that is
seen. These diseases with a well-recognised inflammatory
component are usually treated with general or specific anti-
inflammatory pharmaceuticals with the aim of inducing a clini-
cal benefit. More recently, it has become clear that metabolic
diseases such as atherosclerosis, type 2 diabetes and obesity
have an inflammatory component(6,9–11), albeit low-grade;
however, the extent to which this is causal in the pathology
is not yet clear. These diseases are not usually treated with
anti-inflammatory pharmaceuticals. It is considered that
many dietary factors can influence various aspects of inflam-
mation(1,6); thus, nutrition may play a role in predisposing to
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Fig. 2. An overview of inflammation. C, complement; CRP, C-reactive protein; SAA, serum amyloid A; TNFR, TNF receptor; ra, receptor antagonist; PAI, plasmi-
nogen activator inhibitor; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; CCL, chemokine (C–C motif) ligand; CD62E, E-selectin
endothelial leukocyte adhesion molecule 1; CD62P, P-selectin endothelial leukocyte adhesion molecule 1; CXCL, chemokine (C–X–C motif) ligand; tPA, tissue
plasminogen activator; vWF, von Willebrand factor; IFN, interferon; PLA, phospholipase A; ROS, reactive oxygen species.
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conditions that have an inflammatory component and altered
nutrition may be useful in the prevention or treatment of such
conditions(1,6).
In order to elucidate the role of diet or its component foods,
nutrients and non-nutrients in inflammation, either as a predis-
posing, preventative or therapeutic factor, there is a need to be
able to monitor the inflammatory process in the subjects being
studied. This requires the identification of biomarkers of
inflammation. A biomarker is defined as ‘a characteristic that
is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or phar-
macologic responses to an intervention’(12). However, clear
recommendations on which biomarkers to use and how to
interpret patterns of biomarkers and changes in biomarkers
in the context of inflammation are lacking. The Institute of
Medicine recently presented a general concept for identifi-
cation of biomarkers and surrogate endpoints in chronic
diseases(13). The Institute of Medicine recommended
basing the evaluation process for biomarkers on three steps:
(1) analytical validation of the biomarker (reference range,
accuracy, limits of detection, reproducibility, etc.); (2) qualifi-
cation of the available evidence on an association between
the biomarker and disease states including data showing
the effects of an intervention on both the biomarker and clini-
cal outcomes; (3) use of a utilisation step that primarily
includes the determination of whether analytical validation
and qualification conducted provide sufficient support for
the proposed use of the biomarker(13). The overall aim of
this review is to identify robust and predictive markers, or
patterns or clusters of markers, that can be used to assess
inflammation in human nutrition studies in the general popu-
lation and to create a consensus for grading these biomarkers.
How were the biomarkers chosen?
In order to select likely biomarkers of relevance to nutrition
studies, it was decided to first identify general and disease-
specific markers of inflammation within the circulation
Table 2. Lipid mediators associated with inflammation*
Class Mediator Substrate Receptor(s)
Prostanoids PGD2 Arachidonic acid via COX DP1, DP2
PGE2 Arachidonic acid via COX EP1, EP2, EP3, EP4
PGF2a Arachidonic acid via COX FP
PGI2 Arachidonic acid via COX IP
TXA2 Arachidonic acid via COX TP
PGE1 Dihomo-g-linolenic acid via COX EP1, EP2, EP3, EP4
PGD3 EPA via COX DP1, DP2
PGE3 EPA via COX EP1, EP2, EP3, EP4
Leukotrienes 5-HETE Arachidonic acid via 5-LOX BLT2
5-HPETE Arachidonic acid via 5-LOX OXE
LTB4 Arachidonic acid via 5-LOX BLT1, BLT2
LTC4, D4, E4 (termed cys-LT) Arachidonic acid via 5-LOX CysLT1, CysLT2
15-HETE Arachidonic acid via 15-LOX BLT2
15-HPETE Arachidonic acid via 15-LOX BLT2
12-HETE Arachidonic acid via 12-LOX BLT2
LTB5 EPA via 5-LOX BLT1, BLT2
Lipoxins LXA4 Arachidonic acid via 15-LOX and 5-LOX or 5-LOX
and 12-LOX (transcellular)
FPR2/ALX
Endocannabinoids 2-Arachidonoylglycerol 1,2-Diacylglycerol with arachidonic acid at the sn-2
position
CB1, CB2
Anandamide N-arachidonoylphosphatidylethanolamide via phos-
pholipase D; in turn, N-arachidonoylphosphatidy-
lethanolamide is formed from phosphatidylcholine
with arachidonic acid at the sn-1 position and
phosphatidylethanolamine
CB1, CB2
Resolvins, protectins
and maresins
RvE1 EPA via acetylated COX-2 and 5-LOX (transcellular) RvE1 (ChemR23), BLT1
RvD1 DHA via acetylated COX-2 and 5-LOX or via 15-LOX
and 5-LOX (transcellular)
RvD1 (GPR32), ALX/FPR2
PD1 (NPD1) DHA via 15-LOX and LOX (transcellular) Not yet known
MaR1 DHA via 15-LOX and 12-LOX (transcellular) Not yet known
Lysolipids PAF Phosphatidylcholine with diethyl ether link at the sn-1
position
PAF-R
Lyso-PA Phosphatidic acid, which in turn is synthesised
from phosphatidylcholine
LPA1, LPA2, LPA3, LPA4,
LPA5, LPA6
Sphingosine-1-phosphate Sphingosine, which in turn is synthesised from
ceramide
S1P1, S1P2, S1P3, S1P4, S1P5
COX, cyclo-oxygenase; TX, thromboxane; HETE, hydroxyeicosatetraenoic acid; LOX, lipoxygenase; HPETE, hydroperoxyeicosatetraenoic acid; cys, cysteinyl; LT, leukotriene;
LX, lipoxin; Rv, resolvin; P, protectin; NP, neuroprotectin; MaR, maresin; PAF, platelet-activating factor; Lyso-PA, lysophosphatidic acid; DP, EP, FP, IP, TP, prostanoid
receptors; BLT, leukotriene B4 receptors; OXE, oxoeicosanoid receptor; D4, E4, Leukotriene receptors; FPR2, formyl peptide receptor 2; ALX, oncogenic receptor tyrosine
kinase; CB, cannabinoid receptor; ChemR23, chemokine receptor-like 1 (also known as Chemerin receptor 23); RvD, resolving D; GPR32, G protein-coupled receptor 32;
LP, lysophospholipid; S1P, sphingosine-1-phosphate.
* Note that the listing is not exhaustive.
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Table 3. Soluble peptides associated with inflammation*
Soluble inflammatory
marker
Main producing
cells/organs Target/receptors (when relevant) Biological function(s)
Cytokines/chemokines
IL-1b Immune cells IL-1R1 and IL-1R2 expressed mainly on leucocytes (also
hypothalamus)
Fever, neutrophil attraction and activation, amino acid release by muscle,
collagen production by fibroblasts, B and T lymphocyte activation, acute-
phase protein synthesis by liver
IL-6 Bone, endothelial, epi-
thelial, immune and
muscle cells
Hepatocytes and leucocytes expressing IL-6R, i.e.
IL-6Ra/GP130 complex (also hypothalamus)
Fever, acute-phase protein synthesis, amino acid release by muscle, fatty
acid release from adipose tissue, neutrophil and lymphocyte activation,
inhibition of TNF and IL-1 and activation of IL-1ra and IL-10 secretion
IL-10 Immune cells IL-10Ra (or IL-10R1) combined with IL-10R2 expressed by
innate and adaptive leucocytes
Decreases pro-inflammatory cytokine expression, reduces Th17 generation,
reduces MHC class II and co-stimulatory molecule expression by anti-
gen-presenting cells, improves B-cell survival and antibody production
IL-12 (IL-12A or
p35 þ IL-12B or p40
heterodimeric)
Immune cells IL-12R-b1 and IL-12R-b2 heterodimer expressed on leuco-
cytes (T and NK cells)
Pro-Th1 and anti-Th2 function, Th1 and NK cell proliferation, stimulation of
T and NK cell cytotoxic activity, up-regulation of IL-18R, activation of
macrophages, anti-angiogenic
IL-17A Immune cells (Th17
cells)
IL-17R (IL-17RA, IL-17RB and IL-17RC) expressed on
endothelial and epithelial cells as well as on keratinocytes,
fibroblasts and some leucocytes
Potentiates chemokine and pro-inflammatory cytokine release, triggers anti-
microbial peptide secretion, clear role in skin protection against bacterial
and fungal infections, involved in allergic responses
IL-18 Epithelial and immune
cells
IL-18Ra (or IL-1Rrp) and IL-18Rb (or IL-18RAP) expressed
on leucocytes, endothelial and smooth muscle cells
Induction of IL-1b, IFN-g and TNF production. In combination with IL-12
suppresses Th2-mediated B-cell responses (IgE and IgG1 secretion)
IL-23 (IL-23A or
p19 þ IL-12B or p40
heterodimeric)
Immune cells IL-12R-b1 and IL-23R heterodimer expressed on T cells Directs T-helper cell differentiation (Th17), induces IFN-g and IL-12
production
IFN-g Epithelial and immune
cells
IFNGR1 and IFNGR2 heterodimeric receptor expressed
mainly on APC but also on epithelial, NK and T cells
NK cell and macrophage activation, stimulates expression of MHC I and II
on antigen-presenting cells, promotes Th1 differentiation, suppresses
Th2 differentiation, viral replication inhibition
TNF Adipocytes, epithelial,
endothelial, immune
and muscle cells
TNFR1 and TNFR2 expressed on a wide variety of cells and
organs (leucocyte, muscle, adipocytes, hypothalamus,
etc.)
Fever, acute-phase protein synthesis, procoagulation, Th-cell differen-
tiation, cachexia, apoptosis, inhibits viral replication, antitumour activity,
induction of TNFR shedding as sTNFR
TNFR (TNFR1 and
TNFR2)
Adipocytes, epithelial,
immune and muscle
cells
Binds TNF (which also induces its shedding) At high concentration inhibits TNF function (competition with membrane-
bound receptors). At low concentration, can stabilise TNF trimeric
structure and improve half-life of TNF
MIP-2a (CXCL2;
GROb; GRO-2)
Immune cells CXCR2 expressed on neutrophils, mast cells, keratinocytes
and endothelial cells
Recruitment of leucocytes and haematopoietic stem cells
IL-8 (CXCL8) Epithelial, endothelial
and immune cells
CXCR1 and CXCR2 expressed on neutrophils, mast cells,
keratinocytes and endothelial cells
Neutrophil (and basophil) attraction and activation to the site of
inflammation, angiogenic properties, stimulation of acute-phase
protein synthesis
IP-10 (CXCL10) Epithelial, endothelial
and immune cells
CXCR3-A or CXCR3-B expressed on activated T cells, NK
cells, epithelial and endothelial cells
Recruitment/trafficking of leucocytes and promotion of adhesion to
endothelial cells. Expression largely controlled by IFN-g
MCP-1 (CCL2) Epithelial, endothelial
and immune cells
CCR1 and CCR2 expressed on monocytes, macrophages,
dendritic cells and endothelial cells, as well as on some
lymphocyte subsets
Leucocyte recruitment (monocytes, dendritic cells and memory cells); some
action on mast cell degranulation
MIP-1a (CCL3) Immune cells CCR1, CCR4 and CCR5 expressed on monocytes, macro-
phages, dendritic cells and endothelial cells mainly, as well
as on some lymphocyte subsets
Leucocyte recruitment (monocytes, B and T cells, as well as eosinophils)
RANTES (CCL5) Epithelial, endothelial
and immune cells
CCR1, CCR3, (CCR4) and CCR5 expressed on monocytes,
macrophages, dendritic cells and endothelial cells mainly,
as well as on some lymphocyte subsets and airway
epithelium
Leucocyte recruitment (T cells, basophils and eosinophils), NK cell
activation. Highly expressed upon pro-inflammatory cytokine exposure
Acute-phase proteins
C-reactive protein Liver Phosphatidylcholine residues Host defence (clearance of pathogens and dead cells) by opsonisation and
complement activation
a-1-Antitrypsin Liver Binds proteases such as elastase Serpin protease inhibitor (tissue protection)
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Table 3. Continued
Soluble inflammatory
marker
Main producing
cells/organs Target/receptors (when relevant) Biological function(s)
von Willebrand factor Endothelial cells and
megakaryocytes
gp1b platelet receptor Haemostasis/platelet adhesion/factor VIII carrier
Serum amyloid A Liver FPRL1, CD36, SR-BI/CLA-1, P2X7 and TLR Cholesterol transport, chemoattraction, opsonin, potentiates matrix metallo-
proteinase 9 activity, Th17 generation and pro-inflammatory cytokine
(IL-1b, IL-6 and TNF) expression
Fibrinogen Liver Thrombin substrate Blood coagulation (conversion into fibrin by thrombin)
a-1-Antichymotrypsin Liver, also pancreas Binds and inactivates proteases such as cathepsin G or
chymase
Serpin protease inhibitor (tissue protection)
Complement C3 Liver Bacterial surfaces Innate defence (complement system activation) anaphylatoxin and opsonin
Complement C4 Liver Complement R1, endothelium Innate defence (complement system activation) anaphylatoxin and opsonin
IL-1ra Adipocytes, epithelial
and immune cells
IL-1R1 and IL-1R2 expressed mainly on leucocytes (also
hypothalamus)
Natural inhibitor of IL-1a and IL-1b (competition for the same receptors)
Plasminogen activator
inhibitor-1
Adipocytes and endo-
thelial cells
tPA, uPA and matrix metalloproteinases are known targets Serine protease inhibitor (serpin) inhibiting tPA and uPA, leading to lower
plasminogen activation and hence reduction of fibrinolysis
Adhesion markers
VCAM-1 (CD106) Endothelial cells Binds to integrins VLA-4 and a4b7 Adhesion of leucocytes to endothelial cells. Expression stimulated by
pro-inflammatory cytokines (IL-1 and TNF) as well as IL-4. Soluble form
displays lymphocyte chemotactic properties
ICAM-1 (CD54) Epithelial, endothelial
and immune cells
Binds to CD11a/CD18 (LFA-1) or CD11b/CD18 (MAC-1)
integrins
Adhesion of leucocytes to endothelial cells or antigen-presenting cells.
Expression stimulated by pro-inflammatory cytokines (IL-1 and TNF).
Soluble form displays macrophage activation properties and reduction of
leucocyte adhesion to endothelium
E-selectin (CD62E) Endothelial cells Binds sialylated carbohydrates (Lewis A and Lewis X) on
leucocyte surface (glycoproteins and glycolipids).
Proposed molecules PSGL-1 and ESL-1
Adhesion/recruitment of leucocytes to endothelial cells. Expression stimu-
lated by pro-inflammatory cytokines (IL-1 and TNF). No clear specific
functions for soluble form
P-selectin (CD62P) Endothelial cells and
platelets
Binds sialylated carbohydrates (Lewis A and Lewis X) on
leucocyte surface (glycoproteins and glycolipids). Known
molecules PSGL-1 and CD24
Adhesion/recruitment of leucocytes to endothelial cells. Aggregation of
platelets. Expression stimulated by histamine and thrombin. No clear
specific functions for soluble form
Others
Leptin Adipocytes Leptin R expressed by neurons in the hypothalamus Regulation of food intake (appetite), energy expenditure, adipose tissue
mass
tPA Endothelial cells Interacts with plasminogen, fibrinogen, LRP1, neuroserpin Serine protease involved in fibrinolysis by enzymatic conversion of plasmi-
nogen into plasmin
sPLA2 Ubiquitous Phospholipids are substrates Recognition and hydrolysis of sn-2 acyl-bound phospholipids releasing a
NEFA and a lysophospholipid. Sn-2 position often contains arachidonic
acid (important eicosanoid precursor). PAF precursor generation. sPLA2
has antimicrobial properties. IFN-g is known to activate sPLA2
Antimicrobial peptides Paneth cells and
immune cells
Bacteria and some viruses Targeted microbe killing
Autoantibodies B cells and plasma cells Self antigens (protein, DNA, lipids, etc.) Cell/tissue destruction
IgE B cells and plasma cells Fc1R1 and Fc1R2 expressed on basophils and mast cells
(plus other granulocytes and platelets)
Defence against parasites and allergic reactions (allergen recognition
followed by mast cell degranulation and basophil secretion of Th2
cytokines and pro-inflammatory mediators)
ra, receptor antagonist; Th, helper T; NK, natural killer; IL-18Ra, IL-18 receptor alpha; IL-1Rrp, IL1 receptor-related protein; IL-18Rb, IL-18 receptor beta; IL-18RAP, IL-18 receptor accessory protein; IFN, interferon; APC, antigen-
presenting cells; R, receptor; MIP, macrophage inhibitory protein; CXCL, chemokine (C–X–C motif) ligand; GRO, growth-regulated protein; CXCR, chemokine (C–X–C motif) receptor; IP-10, interferon g-induced protein 10;
MCP, monocyte chemoattractant peptide; CCL, chemokine (C–C motif) ligand; CCR, chemokine (C–C motif) receptor; RANTES, regulated on activation, normal T expressed and secreted; TLR, Toll-like receptor; tPA, tissue
plasminogen activator; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; sPLA2, soluble phospholipase A2; PAF, platelet-activating factor; GP130, glycoprotein 130; FPR, formyl peptide receptor;
CD, cluster of differentiation; SR-BI, scavenger receptor class B member 1; P2X7, P2X purinoceptor 7; uPA, urokinase receptor; LFA-1, lymphocyte function-associated antigen 1; MAC-1, macrophage-1 antigen; PSGL-1,
P-selectin glycoprotein ligand 1; ESL-1, E-selectin ligand 1; LRP1, Low density lipoprotein receptor-related protein 1; Fc1R1, high-affinity IgE receptor 1; Fc1R2, high-affinity IgE receptor 2.
* Note that the listing is not exhaustive.
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(i.e. soluble within plasma/serum or as circulating cells)
and within tissue sites. These markers were identified by
considering a range of conditions with a recognised
inflammatory component elicited within different body com-
partments (i.e. adipose tissue, brain, gastrointestinal tract, vas-
cular wall, joints, airways or skin). The objective of
considering such a wide range of pathological conditions
was to identify those markers that are common to inflam-
mation, irrespective of its causative trigger. The following
four general families of inflammatory disease are discussed
herein: metabolic conditions (obesity, type 2 diabetes and
cardiovascular disease (CVD)), immune-mediated inflamma-
tory diseases (RA, Crohn’s disease and psoriasis), allergic
diseases (asthma and atopic dermatitis) and a prototypical
neurodegenerative disease (Alzheimer’s disease). These dis-
eases each have different molecular triggers, which are
mostly exogenous to the host individual but are endogenous
in some cases. For each disease, Table 4 lists the plasma/
serum (hereafter termed soluble), blood cell and tissue markers
of inflammation commonly reported in the literature related to
that disease; the listing is not exhaustive.
Although inflammation-induced tissue damage occurs in
an organ-specific manner (adipose tissue, vascular wall,
joints, skin, gut, airways and brain) in the different diseases
or conditions, there is some commonality among the
responses and markers seen in the different organs (summar-
ised in Tables 5 and 6 for soluble markers and blood cellular
markers, respectively). Indeed, although triggers, localisation
and resulting clinical symptoms are different, many of the pro-
cesses, cells and molecules involved in the actual inflamma-
tory response are remarkably similar. Most, if not all, of the
chronic inflammatory diseases considered here are character-
ised by an increase in the number of leucocytes in the blood-
stream and by overproduction and appearance in the
bloodstream of increased concentrations of inflammatory
cytokines (TNF, IL-1b, IL-6 and interferon-g) and chemokines
(IL-8 and monocyte chemoattractant protein (MCP)-1). Elev-
ated levels of these mediators act to amplify the inflammatory
process (e.g. by attracting further inflammatory cells to the
site), contribute to tissue destruction, elicit systemic effects
(e.g. hepatic CRP synthesis) and, in many cases, actually
cause the clinical symptoms observed (Fig. 2; Table 4).
Thus, a consideration of a wide range of inflammatory dis-
eases affecting distinct sites within the body has enabled the
identification of a set of ‘common’ or ‘general’ markers of
inflammation that can be measured in the bloodstream
(Tables 5 and 6). The selection of soluble markers of inflam-
mation has focused on peptides and proteins; lipid mediators
have not been considered further because of their instability
and relative difficulty of measurement. For most of the soluble
markers identified (Table 5), there is no commonly accepted
normal range of concentrations. In contrast, for the blood cel-
lular markers of inflammation (Table 6), there is a generally
accepted normal range and some of these markers are used
clinically.
In addition to the general, non-specific markers of inflam-
mation identified above, there are a number of inflammatory
markers that are more disease specific (Table 4). Sometimes
these markers are present at the site of the inflammatory
locus, such as thymic stromal lymphopoietin in skin lesions
in atopic dermatitis. On other occasions, they may appear in
the circulation (e.g. rheumatoid factor in RA). Because the
aim of this evaluation of inflammatory markers is to identify
those to be assessed in nutrition studies in the general popu-
lation, disease-specific markers are not considered to be of rel-
evance to this aim. Likewise, assessment of general, non-
specific inflammatory markers at sites of disease activity (e.g.
cytokines in synovial fluid in RA, in bronchoalveolar lavage
fluid in asthma, in skin lesions in psoriasis or in gut mucosa
in Crohn’s disease) was not considered relevant to the non-
disease setting. For these reasons, inflammatory markers that
are disease specific and assessment of inflammatory markers
in tissues or lesions are not further considered here. Thus,
this review is restricted to the consideration of inflammatory
markers in the blood, either soluble markers in plasma/
serum (Table 5) or circulating cells (Table 6).
Key messages
(1) Acute inflammation is a normal physiological response
critical to maintain homeostatic control, but when it
becomes chronic, inflammation contributes to the patho-
physiology of a range of diseases.
(2) Common soluble markers of inflammation include
cytokines, chemokines, lipids, acute-phase proteins and
adhesion molecules.
(3) Common blood cellular markers of inflammation include
various subclasses of leucocytes. The same markers are
involved in both acute and chronic inflammatory
processes, meaning that the markers themselves, in iso-
lation, cannot be used to distinguish the two processes.
Modifiers of inflammatory markers
There is a considerable between-individual variation in the
numbers of leucocytes and of leucocyte subclasses and in
the concentrations of the soluble markers of inflammation.
There is no generally accepted ‘normal range’ for most of
these markers, although there are clinically accepted normal
ranges for total leucocytes and the leucocyte subclasses
(Table 6). A number of modifiers, other than the presence of
an inflammatory trigger, have been shown to influence the
concentrations of these markers; these modifiers include
age, body fatness, physical (in)activity, sex, genetics, smoking,
gut microbiota composition, diet, use of medications and
other factors such as emotional stress, pollution, viral infection
and sleep behaviour (Fig. 3; Tables 5 and 6). These modifiers
should all be considered when designing a study aimed at
measuring inflammatory biomarkers.
Influence of age
A certain degree of inflammation may be part of adaptability
and homeostasis in older people, and it has been demon-
strated that their ability to mount a vigorous inflammatory
Biomarkers of inflammation S9
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Table 4. Markers associated with inflammation in specific diseases
Metabolic Autoimmune Allergic Neurodegenerative
Example of
disease Obesity Type 2 diabetes Cardiovascular Rheumatoid arthritis Psoriasis Crohn’s disease Atopic dermatitis Allergic asthma Alzheimer’s disease
Key molecular
drivers of the
inflammatory
response
Infiltration of macro-
phages into adi-
pose tissue in
response to meta-
bolic stress; gut
microbiota
(possibly)
Infiltration of macro-
phages into adi-
pose tissue in
response to meta-
bolic stress
Uptake of oxidised
LDL by macro-
phages in the
vessel wall; endo-
thelial injury
Unknown Skin streptococci
and unknown
host factors
Gut microbiota and
unknown host
factors
Allergens and other
irritants
Allergens and other
irritants
Modified and mis-
folded proteins
Tissue markers Adipose tissue:
inflammatory cell
infiltrate
(especially macro-
phages), inflam-
matory gene
expression and
cytokine
expression
Adipose tissue:
inflammatory cell
infiltrate
(especially macro-
phages), inflam-
matory gene
expression and
cytokine
expression
Vessel wall or
plaque material:
macrophage and
T-cell infiltrate
Synovial fluid: T
cells, macro-
phages, neutro-
phils, synovio-
cytes plus
inflammatory
mediators
(cytokines,
eicosanoids)
Skin lesions:
Th1/Th17 cells,
some neutrophils,
activated kerati-
nocytes, IFN-g,
VEGF, IL-17,
TNF, defensins
Gut mucosa: cyto-
kines and chemo-
kines (TNF, IL-18,
IL-23, IFN-g,
CXCL10), stress
markers (GRP78,
CPN60, PKR),
activated MAPK,
NF-kB, SMAD7;
faeces: calprotec-
tin, S100 proteins
(S100A12,
S100A8/A9)
Skin lesions: T cells,
eosinophils, mast
cells, thymic stro-
mal lymphopoie-
tin, Th2-type
cytokines
Sputum/bronchoal-
veolar lavage
fluid: leucocytes,
eosinophils, mast
cells, eosinophilic
cationic protein,
TNF, IL-4, IL-5,
IL-6, IL-8, IL-12,
IL-13, osteopon-
tin, eotaxin,
cysteinyl-LT,
PGD2, tryptase;
exhaled NO; lung
function in
response to
indirect challenge,
e.g. cold air;
urine: eosinophilic
cationic protein,
LTE4, PGD2
metabolite
Plaque: activated
microglia and
reactive astro-
cytes, inflamma-
tory proteins
including comp-
lement factors,
acute-phase pro-
teins, pro-inflam-
matory cytokines
and chemokines
(as in blood),
increased Ab42,
total tau; CSF:
low levels of
Ab42, increased
phosphorylated
tau (P-tau181)
Blood cellular
markers
Total leucocytes,
total neutrophils,
CD11b (granulo-
cytes), CD11c
and CD66b
(monocytes),
T cells
Total leucocytes Total leucocytes Possibly low Treg
numbers/function,
Th1- and Th2-
type cytokine
responses
skewed to Th1
Total leucocytes,
total neutrophils
Total leucocytes,
total neutrophils,
Th1 and Th17
cells, macro-
phages (CD163þ,
CD68þ, S100þ)
Total eosinophils,
Th1- and Th2-
type cytokine
responses
skewed to Th2
Total eosinophils,
Th1- and Th2-
type cytokine
responses
skewed to Th2
B cells (decreased),
decreased
expression of acti-
vation marker
CD69 and chemo-
kine receptors on
T cells, low per-
centage of naive
CD4 T cells
Soluble inflam-
matory
markers
CRP, SAA, fibrino-
gen, cytokines
(TNF, IL-1, IL-1ra,
IL-6, IL-8, IL-17,
IL-18, TNFR, lep-
tin), chemokines
(CCL2, CCL3,
CCL5), vWF,
adhesion mol-
ecules (VCAM-1,
ICAM-1, E-selec-
tin, P-selectin),
PAI-1, C3, low
adiponectin
CRP, SAA, fibrino-
gen, cytokines
(TNF, IL-1, IL-1ra,
IL-6, IL-8, IL-17,
IL-18, TNFR, lep-
tin), chemokines
(CCL2, CCL3,
CCL5), vWF,
adhesion mol-
ecules (VCAM-1,
ICAM-1, E-selec-
tin, P-selectin),
PAI-1, low adipo-
nectin
CRP, SAA, fibrino-
gen, cytokines
(TNF, IL-1, IL-1ra,
IL-6, IL-8, TNFR),
chemokines
(CCL2), vWF,
adhesion mol-
ecules (VCAM-1,
ICAM-1, E-selec-
tion, P-selectin),
PAI-1, a-1-anti-
trypsin, sPLA2,
NO
Rheumatoid factor,
autoantibodies,
CRP, cytokines
(TNF, IL-1, IL-1ra,
IL-6, IL-17, IFN-g,
TNFR)
CRP, TNF, other
cytokines
Antimicrobial and
autoantibodies,
CRP, cytokines
(TNF, IFN-g, IL-
1b, IL-6, IL-10, IL-
12, IL-17, IL-18,
IL-23), chemo-
kines (CCL2,
CCL3, CCL5,
CXCL2, CXCL8,
CXCL10)
Total and allergen-
specific IgE
Total and allergen-
specific IgE, cyto-
kines (Th2-type
dominated) and
chemokines
CRP, TNF, IL-6,
antichymotrypsin,
C3, C4
Th, helper T; IFN, interferon; VEGF, vascular endothelial growth factor; CXCL, chemokine (C–X–C motif) ligand; GRP, glucose-related protein; PKR, protein kinase R; SMAD, Intracellular proteins that transduce extracellular sig-
nals from TGF beta ligands; CPN, chaperone; MAPK, mitogen-activated protein kinase; LT, leukotriene; CRP, C-reactive protein; SAA, serum amyloid A; ra, receptor antagonist; R, receptor; CCL, chemokine (C–C motif) ligand;
vWF, von Willebrand factor; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; PAI, plasminogen activator inhibitor; sPLA2, soluble phospholipase A2; C, complement.
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Table 5. Soluble markers of inflammation and their associated modifying factors
Marker
Typical range reported
in healthy subjects*
Association with
increasing age
Association
with increasing
body fatness
Association
with habitual
physical activity
Association
with smoking References
Cytokines/chemokines
TNF 0·75–5 ng/l $ / " " # / $ " 18, 19, 22, 55–57, 77, 110, 133, 301
TNFRI and TNFRII 400–700 ng/l " " # 24, 25, 55, 64, 302, 303, 304
IL-6 0·4–1·4 ng/l $ / " " # " 14, 18, 20, 21, 24, 57, 61, 62, 77, 110, 130–132, 305–307
IL-1b 200–500 ng/l $ / " / # " $ $ 18, 19, 21, 60, 110, 301
IL-8 2–10 ng/l $ / " $ / " " $ 24, 63, 64, 77, 308, 309, 310
IFN-g 1–5 ng/l " 24
CCL2 200–400 ng/l $ / " " 24, 31, 63, 65, 66, 77
CCL3 0·1–11·3 ng/l " 308, 309
CCL5 20–50 ng/ml " $ $ $ 308, 309
Acute-phase proteins
CRP 0·1–10 mg/l† " " # " 14, 26, 42, 62, 67, 68, 77, 135, 136, 138, 139, 311, 312
SAA 15–35 mg/l " " $ / " 42, 141, 256, 313
Fibrinogen 1500–4000 mg/l " " # " 14, 20, 28, 135–137, 139, 140, 314, 315
Von Willebrand factor 5–15 mg/l " " 316–320
Antichymotrypsin 300–460 mg/l "
C3 1–3 mg/l " # " 321–325
IL-1ra 350–700 ng/l " " $ 14, 21, 25, 58–60, 326
Soluble adhesion markers
VCAM-1 500 ng/ml " " # 29, 30, 57, 70
ICAM-1 175–200 ng/ml " " # " 58, 70–73, 130, 327
E-selectin 43–80 ng/ml $ " # " 30, 70, 72–74, 130, 328
P-selectin 50–60 ng/ml " " # 57, 71
Adipokines
Leptin 10 ng/ml $ " # $ / # 55, 61, 65, 75, 327, 329
Adiponectin 5–15 mg/l $ / " # " # 33, 34, 76–78, 330
R, receptor; IFN, interferon; CCL, chemokine (C–C motif) ligand; CRP, C-reactive protein; SAA, serum amyloid A; C, complement; ra, receptor antagonist; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion
molecule; ", positive association; #, negative association; $, no clear association.
* These values are based on groups of healthy subjects in studies published in scientific literature. These are therefore indicative of what could be expected in such populations.
† Values .10 mg/l considered to be indicative of inflammation beyond ‘low grade’.
B
io
m
ark
e
rs
o
f
in
fl
am
m
atio
n
S1
1
British Journal of Nutrition
response is associated with enhanced survival(14). On the
other hand, inflammation is considered to play an important
role in the loss of lean body mass and in progression towards
frailty in older persons. Studies investigating a possible effect
of age on inflammatory markers have generally adopted one
of two approaches. The first has been to look for an associ-
ation between age and the concentrations of markers of inter-
est, whereas the second has been to compare marker
concentrations between two or more groups of individuals
of different ages. Studies have generally stratified populations
and set arbitrary thresholds varying from ages .60, 65, 70 to
$75 years to identify aged individuals. These studies, for the
most part, have suggested that ageing is accompanied by a
low-grade chronic inflammatory state, clearly shown by two-
to fourfold higher concentrations of serum levels of several
inflammatory markers such as cytokines and acute-phase pro-
teins in older persons(15). Several studies have reported age-
associated increases in total leucocyte numbers(16,17) and in
soluble concentrations of soluble pro-inflammatory cytokines
such as IL-1(18,19), IL-6(14,18,20,21) and TNF(22,23), although this
has not been seen in all studies(21,24). Others have reported
higher concentrations of IL-1 receptor antagonist(14,21,25) and
of TNF-receptors(24,25) with increased age. In line with these
findings, many studies have reported higher concentrations
of downstream markers such as acute-phase proteins like
CRP(14,26), a1-acid glycoprotein(27) and fibrinogen(14,20,28).
Fewer studies have addressed the relationship of ageing
with chemokines and adhesion molecules, although in some
studies, vascular cell adhesion molecule (VCAM)-1(29,30) and
intercellular adhesion molecule (ICAM)-1(30) have been
shown to have higher concentrations in older persons while
E-selectin was not(30). Similarly, there is some evidence that con-
centrations of MCP-1(31), plasminogen activation inhibitor-1(32)
and adiponectin(33,34) are increased with ageing.
Overall, these changes support a generally increased state
of low-grade chronic inflammation in older people compared
with younger adults. The more limited literature on blood cel-
lular markers would support this contention, but indicates that
numbers and proportions of leucocytes in the older people
differ considerably depending on the state of health of the
individual(35). Although older individuals have been reported
to have increased total leucocytes, the increase in neutrophils,
in particular, has been related to reduced survival in longitudi-
nal studies, whereas total lymphocyte numbers are not signifi-
cantly associated with survival(36). However, within the total
lymphocyte population, there may be decreased numbers of
B cells and increased numbers of CD8 cells in older persons,
which can also have an impact on survival and which to a
great extent depend on microbiological exposures(37).
It is recognised that ageing represents cumulative effects of
exposure to various triggers such as diet, physical (in)activity
and stress, as well as micro-organisms, over the lifetime, and
it is hypothesised that failure of anti-inflammatory mechanisms
to neutralise such inflammatory processes triggered
continuously lifelong plays a role in low-grade chronic inflam-
mation in older people(38). Inflammatory markers in older per-
sons may also be influenced by co-morbidity, medication use
or malnutrition(39–43). However, there are some indications that
once co-morbidities are accounted for, inflammation is still
associated with ageing(14,15). A number of other factors that
may affect and modulate circulating levels of inflammatory
mediators alter with ageing, including body composition, physi-
cal (in)activity, sex hormone concentrations, gut microbiota,
emotional stress and a poor social environment(44–48). It is
likely that in some studies, these confounders have not been
considered when the effect of age on inflammation has been
evaluated(44–48). Thus, it is challenging to dissect out the
effect of ageing per se on inflammatory markers in humans
and essentially impossible to exclude all residual confounding
concomitant modifying factors and lifelong exposures. One
possibility is to examine inflammatory markers in centenarians
as a model of successful ageing. Low levels of the pro-inflamma-
tory cytokine IL-6 and high levels of anti-inflammatory cyto-
kines such as IL-10 and transforming growth factor (TGF)
have been noted in centenarians(49,50), suggesting that these
extremely old persons do not suffer the ‘inflammaging’ noted
in many older persons who do not survive to 100 years of age
or beyond.
Influence of body fatness and fat distribution
As stated earlier, white adipose tissue secretes cytokines and
chemokines, and macrophage and T-cell infiltration is dra-
matically increased in the adipose tissue of obese
humans(51). Obesity is associated with a state of low-grade
chronic inflammation. Total blood leucocyte numbers are
positively associated with obesity and the metabolic syn-
drome(16,17,52–54). Differential leucocyte counts indicate that
neutrophils, but not monocytes or lymphocytes, account for
this predictive potential(17). There are higher concentrations
Table 6. Blood cellular markers of inflammation and their modifying factors
Marker Normal range*
Association with
increasing age
Association
with increasing
body fatness
Association
with habitual
physical activity
Association
with smoking References
Total leucocytes 4–11 £ 109/l " " # " 16, 17, 53, 89, 128, 129
Total neutrophils 2–7·5 £ 109/l " " # " 17, 54, 245
Total T lymphocytes 0·6–2·5 £ 109/l $ " # " 35, 89, 331
Total eosinophils 0–0·4 £ 109/l # " " " 89, 332, 333
Total monocytes 0·2–0·8 £ 109/l " " " # 89, 335
Up arrow, Positive association; Down arrow, Negative association; Double arrow, No clear association.
* Based on data reported in MacLennon & Drayson(336).
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of circulating cytokines and chemokines such as TNF(55–57),
IL-1(58–60), IL-6(57,61,62), IL-8(63,64) and MCP-1(63,65,66) in obese
individuals compared with normal-weight subjects. Several
acute-phase proteins are elevated in overweight and obese
subjects. For example, the circulating concentration of CRP
is higher in obese persons, and obese subjects who lost
weight showed decreased levels of CRP(67,68). A meta-analysis
showed a strong association between Body Mass Index (BMI)
and serum amyloid A concentration(69). Elevated levels of sol-
uble adhesion molecules, such as VCAM-1, ICAM-1, E-selectin
and P-selectin, are found in obese individuals compared with
normal-weight subjects(57,70–74). Leptin concentrations are
higher in obese than in normal-weight subjects(55,61,65,75),
while adiponectin concentrations are lower in obese individ-
uals(76–78). Although these studies have focused on obesity
per se, the distribution of adipose tissue appears to be import-
ant in determining inflammatory burden. Visceral adipose
tissue has a greater production of inflammatory mediators
such as cytokines than subcutaneous adipose tissue, although
the precise contribution of each to the circulating pool is not
clear(79). Furthermore, other adipose tissue depots in so-called
‘ectopic sites’, such as within the liver, heart or skeletal muscle,
may contribute to the production of inflammatory mediators
even in the absence of obesity(80). In this regard, the local pro-
duction of inflammatory molecules by adipose tissue within
the heart may be important; the amount of this tissue and its
proximity to the coronary vessels could contribute to the
development of coronary pathologies(81,82). Although there
has been considerable focus on the role of low-grade chronic
inflammation in overweight, obesity and the metabolic syn-
drome(6), it is important to recognise that underweight also
appears to be associated with low-grade chronic inflam-
mation. For example, adolescent anorexia is associated with
elevated levels of some inflammatory cytokines including
TNF-a(83), and low-grade chronic inflammation is associated
with low body weight in older subjects(84). Several pro-
inflammatory cytokines, most notably TNF-a, have a causal
role in cachexia(85).
Influence of physical (in)activity
Physical (in)activity resulting in inadequate energy expendi-
ture relative to intake may lead to the accumulation of visceral
fat and consequently to the activation of inflammatory
processes associated with this(86). In contrast, physical activity
promotes health and this may relate to the anti-inflammatory
effect of regular exercise, which reduces visceral fat mass
and induces an anti-inflammatory environment(87,88). Subjects
engaged in regular physical activity have lower blood
leucocyte numbers(89). Plasma concentrations of IL-6 are
lower in individuals who undertake regular physical activity
than in those who do not(90). The lower concentrations of
IL-6 in the circulation will subsequently result in lower CRP
levels. Several studies of large population cohorts have
provided evidence for an inverse, independent dose–
response relationship between the level of habitual physical
activity and plasma CRP concentration in both men and
women(91–96). Moreover, CRP levels in 2120 Finnish partici-
pants were associated with obesity indices (positively) and
physical activity (inversely) among both sexes(97). Cross-sec-
tional studies have demonstrated that cardiorespiratory fitness
levels are inversely associated with CRP concentrations
and also the prevalence of elevated CRP concentrations(98).
However, conflicting findings exist and several training inter-
ventions have not produced changes in basal IL-6 or CRP
levels(99–106). There seems to be more consistency in patients
with metabolic or coronary disease and in older individuals
than in healthy or young people. In a relatively large interven-
tion study of exercise training in cardiac rehabilitation
patients, CRP concentration was reduced by 41 %, whereas
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•  Diet
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•  Other (emotional stress, pollution,
   viral infections, sleep behaviour)
•  Tissue damage
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Fig. 3. Factors that influence the status of soluble and cellular markers of inflammation in the bloodstream. Triggers are those factors that can directly initiate
an inflammatory response. Modifiers are endogenous and exogenous factors that may increase or decrease the response induced by a trigger. ER, endoplasmic
reticulum; TLR, Toll-like receptor; TNFR, TNF receptor.
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CRP concentrations did not change in subjects who did not
exercise(107). Rankovic et al.(108) showed that 6 weeks of
aerobic exercise can significantly reduce the inflammatory
state by decreasing CRP and VCAM-1 levels in patients with
stable coronary heart disease. One possible explanation
could be that patients and older people have higher basal
levels of inflammation before becoming physically active
and physical activity is more effective in lowering the CRP
levels in those with the highest initial CRP concentrations(107).
Given that physical activity and obesity are often inversely
related, it is not clear as to whether the anti-inflammatory
health benefits of a physically active lifestyle are due to exer-
cise per se or result from favourable changes in body compo-
sition. A systematic review addressed whether fitness or
fatness has the greatest impact on inflammatory factors(90)
and concluded that both fatness and the lack of fitness are
associated with systemic inflammatory status, although the
relative contributions of both may be dependent on age, dis-
ease status and sex. Different types of exercise to attain and
maintain a state of physical fitness may have different effects
on inflammation(109), although this is little studied.
Influence of sex
Few studies have examined the effect of sex on inflammatory
markers and the literature presents mixed findings. Some
studies have reported no differences between males and
females for most inflammatory markers examined, including
TNF, TNF-receptor, IL-1, MCP-1(24) or IL-6 and ICAM-1(29).
However, in a study of adolescents (aged 13 to 17 years),
although CRP, C3 and C4 concentrations did not differ
between girls and boys, adolescent boys had lower levels of
adiponectin, leptin and L-selectin than girls, whereas girls
had lower levels of ICAM-1, VCAM-1 and plasminogen acti-
vation inhibitor-1 than boys(86). Some investigators have
reported lower IL-1b levels in men(110), whereas others(111)
have found that men have higher levels of IL-1b-secreting
monocytes than women. Importantly, few studies have
reported on sex effects after adjusting for variables that can
affect inflammatory markers, such as body fatness, fat distri-
bution and physical (in)activity. Marques-Vidal(110) showed
in a Swiss population-based sample that males have higher
levels of IL-6 and TNF and slightly but significantly lower
levels of CRP when compared with females in crude analysis
and after adjusting for age, BMI, smoking status and leisure-
time physical activity in multivariate analysis. There is a
need for further population-based studies in healthy adults
to examine sex differences in inflammatory markers taking
into account potential important confounders.
Influence of genetics
Both epigenetic and genomic variations influence the extent
of the response of an inflammatory marker to a given trigger.
Epigenetics refers to chemical modifications to chromatin or
DNA that influence gene expression but are not encoded in
the DNA sequence itself. The two major epigenetic mechan-
isms are the post-translational modification, often acetylation,
of histone proteins in chromatin and the methylation of DNA
itself. DNA methylation occurs at CpG sites of the gene
sequence. Epigenetic variations appear to play an important
role in determining the risk of inflammatory disorders(112–114).
Differences in the methylation status of CpG sites have been
observed in key inflammatory response genes and influence
the expression of those genes(115). This is an area in which
there are likely to be major advances in the next few years.
It is important to note that epigenetic modifications are not
fixed but may be modified by a number of different
exposures, including stress hormones, oxidative stress, pol-
lution and diet. This may partly explain the ability of those fac-
tors to act as modifiers of the inflammatory response.
SNP are variations in the DNA sequence at a single nucleo-
tide that occur in at least 1 % of the population. They can
occur in both coding and non-coding regions of the
genome. It is estimated that the human genome contains
3 million SNP. Genotype is a description of the allele pair pre-
sent at a given site in the genome, and typically there will be
three possible genotypes (e.g. AA, AG and GG). There are
variations in allele frequencies and genotypes among different
human populations because certain alleles and genotypes may
have offered an evolutionary advantage in one geographical
region and not in another. SNP within a coding sequence do
not necessarily change the amino acid sequence of the protein
that is produced, because of the degeneracy of the genetic
code. SNP that are not in protein-coding regions may affect
transcription factor binding or gene splicing or the sequence
of non-coding RNA and, as a result, the gene expression,
and hence the level of the encoded protein may differ
among individuals with different genotypes. It is likely
that SNP occur in regions of the genome associated with
each of the inflammatory proteins being considered here
(e.g. cytokines, chemokines, adhesion molecules, acute-
phase proteins), encoding enzymes responsible for the syn-
thesis of non-peptide inflammatory mediators (e.g. in cyclo-
oxygenase and lipoxygenase enzymes, NADPH oxidase and
inducible NO synthase) and encoding regulatory proteins
such as transcription factors. In addition, such genetic vari-
ations underlie the huge number of possible variants in the
human leucocyte antigens involved in antigen presentation.
This variation in possible human leucocyte antigens allows
an individual to have the potential to deal with an enormous
number of possible antigens that may be encountered. How-
ever, some human leucocyte antigens variants have strong
associations with inflammatory diseases, such as human leuco-
cyte antigens-DR4 with RA. A number of SNP are of functional
significance, meaning that individuals with different genotypes
will produce different levels of a particular inflammatory
mediator in response to a given stimulus or trigger than
other individuals(116–119). Thus, genotype can influence the
plasma concentration of inflammatory markers(116,120,121). For
example, the G to C polymorphism at the 2174 position of
the IL-6 gene has been reported to significantly influence
plasma IL-6 concentrations: mean concentrations (pg/ml)
after adjusting for age, BMI, sex and smoking were 2·74 for
GG homozygotes, 2·64 for heterozygotes and 1·63 for CC
homozygotes(116). Similarly, the polymorphism at the þ252
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position of the TNF-b gene significantly affected plasma TNF
concentrations in patients with sepsis: median concentrations
(pg/ml) were approximately 200 for B1 homozygotes, 250 for
heterozygotes and 600 for B2 homozygotes(120). The genotype
of certain inflammatory genes has been associated with the
risk or severity of outcome in inflammatory disease(122,123),
infectious disease(123,124) and cancer(123,125).
Ethnicity is related to genetic variation. The concentrations
of some inflammatory markers have been shown to differ
among ethnic groups(126) and the prevalence of many of the
common inflammatory diseases differs according to ethnicity.
However, in addition to genetics, ethnic groups often differ in
a number of the other modifying factors, which may contrib-
ute to the observed differences in inflammatory markers. In
a systematic review and meta-analysis involving 221 287
people from eighty-nine studies, median CRP concentrations
were 2·60 (95 % CI 2·27, 2·96), 2·51 (95 % CI 1·18, 2·86), 2·34
(95 % CI 1·99, 2·80), 2·10 (95 % CI 1·77, 2·30) and 1·01 (95 %
CI 0·88, 1·18) mg/l in African Americans, Hispanics, South
Asians, Caucasians and East Asians, respectively(127). The
differences among groups were retained after adjusting for
age and BMI.
Influence of smoking
Cigarette smoke contains a variety of oxidant molecules in
high amounts, inducing a strong oxidative stress in the
smoker. In turn, oxidative stress can induce an inflammatory
response(1). Indeed, it has been established in several
population-based studies that smoking is associated with a
low-grade chronic inflammatory state, as shown by higher
blood leucocyte numbers(128,129) and higher circulating concen-
trations of acute-phase proteins and cytokines. Several studies
have reported elevated circulating concentrations of pro-
inflammatory cytokines such as IL-6(130–132) and TNF(133,134)
in smokers compared with non-smokers. A number of studies
have reported that CRP and fibrinogen concentrations are
higher in smokers than in non-smokers(135–140). CRP and fibri-
nogen concentrations are found to correlate significantly with
the years of smoking, even after smoking cessation. In the Multi-
national MONItoring of trends and determinants in
CArdiovascular disease (MONICA) study, for example, CRP
concentrations were still elevated 10 years after quitting smok-
ing(136). Some adhesion molecules are also increased in the
serum of smokers compared with non-smokers, including
ICAM-1, P-selectin and E-selectin(130,141). Taken as a whole,
these are strong data supporting that smoking is associated
with low-grade chronic inflammation. Fewer studies have
investigated the impact of long-term passive smoking in non-
smokers on inflammatory markers; those studies that have
been published present inconsistent findings. In a recent
study on 200 non-smoking US truck industry workers, no stat-
istically significant association was found between chronic
exposure to second-hand smoke and systemic inflammatory
markers such as IL-6, CRP or ICAM-1(142). Furthermore, in
7600 never-smoking adults included in National Health
and Nutrition Examination Survey (NHANES) III, no significant
association was found between CRP and second-hand smoke
exposure, measured as serum cotinine level; however, fibrino-
gen was significantly higher in subjects with detectable but
low cotinine levels(143). However, in another study conducted
on 5000 older British non-smoking subjects, serum cotinine
level was positively associated with CRP, fibrinogen, von
Willebrand factor and tissue plasminogen activator(144).
Influence of gut microbiota
Humans co-evolved with gut microbes, which represent more
than 3 million genes from several hundreds of bacterial
species. There is evidence that the nature of the gut micro-
biota influences inflammatory processes, particularly within
the gastrointestinal tract, but perhaps also systemi-
cally(145–149). Thus, in animal models of IBD, disease initiation
strongly depends on the presence of commensal bacteria and,
conversely, in germ-free animals, IBD hardly develops(150,151).
In support of this, human studies have revealed that dysbiosis
(gut microbiota alteration) is a common feature in patients
with IBD in which the overall bacterial diversity is reduced
and species belonging to the phyla Actinobacteria and Proteo-
bacteria are over-represented(151–154) while the phylum Firmi-
cutes is reduced, especially Faecalibacterium prausnitzii,
which has anti-inflammatory properties(155,156). However, it
is still unclear whether these changes are responsible for caus-
ing disease or are a result of other changes in the gut environ-
ment that result from inflammatory reactions and mucosal
tissue damage. Nonetheless, some recent studies have
reported positive effects of using probiotics, prebiotics and
their combination (termed synbiotics) in IBD by a restoration
of a healthy gut microbiota(157,158). This suggests that there is
potential for treating IBD through microbiota manipulation
and modifications of interactions with the gut immune
system. These findings provide a rationale for microbial
characterisation in many other inflammatory diseases, such
as psoriasis and allergic asthma. As in IBD, specific alterations
of skin and airway microbiota are observed in patients with
inflammatory diseases manifested at these sites(159–164). More
recently, gut microbiota in atopic dermatitis and in obese
people has also been carefully addressed and a specific profile
was found, indicating that gut commensals may also exert
remote effects(145,165,166). However, the precise causal role
and the mechanisms involved remain to be established.
Recent findings have also suggested that gut microbiota is a
factor in metabolic diseases, as reviewed recently(167,168). It
has been demonstrated that the gut microbial profile is
specific to the metabolic phenotype in mice and humans
(i.e. obese v. lean and diabetic v. healthy). However, a clear
demonstration connecting intestinal microbiota to metabolic
diseases remained absent until recently. Indeed, Serino
et al.(169) showed that diabetic mice fed a high-fat diet and
that developed diabetes display a specific alteration of gut
microbiota with increased gut paracellular permeability leading
to higher endotoxaemia and subsequent systemic low-grade
inflammation and metabolic syndrome. Conversely, mice
under the same feeding protocol that did not develop disease
had no gut microbiota alteration(169,170). The same specific gut
microbiota alterations have also been reported in obese v. lean
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human subjects (reduced global diversity and relative increase
in the ratio of Bacteroidetes:Firmicutes). F. prausnitzii
was reduced in obese diabetic subjects compared with lean
controls and was negatively correlated with serum levels of
circulating inflammatory markers such as CRP and IL-6 in
these subjects(171). These changes affect the metabolic potential
of the gut microbiota and support an increased capacity to har-
vest energy from the diet in obese people(172–174). These fea-
tures of obesity are transmissible as faecal material transfer
from obese human adults to germ-free mice resulted in higher
total body fat accumulation over time in contrast to lean
human adult faecal material transfer(172–174).
Influence of diet
The influence of diet on soluble markers of inflammation in
different contexts has been described in detail elsewhere(1,6)
and will not be considered further here.
Influence of medication
It is obvious that whether specific or non-specific to particular
disease processes and pathways or to a particular disease,
pharmacologic treatment of inflammation is bound to greatly
influence biomarker levels. A classic example is the influence
of corticosteroids in autoimmune, allergic or mucosal inflam-
matory conditions; corticosteroids are powerful modifiers of
cytokines and growth factors that influence other biomarkers
such as CRP levels in RA and eosinophil levels in asthma.
Indeed, such biomarkers are valuable in monitoring thera-
peutic responses and adherence to treatment. Selective treat-
ments such as targeted biologics (e.g. anti-TNF therapy in
inflammatory joint and bowel diseases) can also influence bio-
markers and, again, these may be used to monitor therapy. It
is, therefore, of utmost importance when using biomarkers for
clinical decision making that any concurrent therapy that may
influence their level or expression is taken into account.
Influence of other modifiers
In addition to the modifiers already considered, inflammatory
biomarkers may be influenced by emotional stress(175–177),
exposure to pollution(178) and sleep behaviour(179) among
other factors.
Summary
Among non-diseased individuals, the concentrations of the
soluble markers and the numbers of some of the cellular mar-
kers of inflammation are altered with increasing age, body fat-
ness and physical (in)activity, and are modified by genetics,
smoking status, gut microbiota and medication use among
other factors (Fig. 3). Typically, a number of the panel of
inflammatory markers identified are altered in the same direc-
tion in response to a given modifying factor (Tables 5 and 6).
Thus, there is little specificity in the inflammatory markers
whose concentrations are changed during inflammatory
states or which are sensitive to modifying factors. Thus, it is
not possible to identify a single marker, or even a small
number of markers, to define inflammation and to use as a
target or targets in studies evaluating nutritional interventions.
Therefore, it is likely to be important to identify patterns or
clusters of markers that provide an inflammatory signature; it
would seem likely that these patterns or clusters would
include at least some of the individual markers considered
here so far.
Key messages
(1) There are a number of endogenous and exogenous modi-
fiers that influence the levels of inflammatory markers
resulting in significant between-individual variation.
(2) These modifiers include age, body fatness, physical
(in)activity, sex, genetics, smoking habits, diet, the com-
position of the gut microbiota and the use of certain
medications.
(3) These modifiers should be recognised, and, where poss-
ible, controlled for, when nutrition studies are designed.
Challenge models
Why challenge models are relevant
The forgoing discussion has focused on individual markers of
inflammation typically measured in the blood of individuals in
the resting (e.g. fasting) state. Such measurements may differ-
entiate between those individuals with an overt inflammatory
disease and those without, and may also indicate the effects of
influencing factors such as age, body fatness, physical (in)ac-
tivity, genetics, smoking habit and the composition of the gut
microbiota on chronic inflammatory tone. However, such
measurements provide little information about an individual’s
(acute) inflammatory response to a challenge. It has been
suggested that dynamic responses to challenges provide a
more sensitive and meaningful indication of health(180,181).
More specifically, the dynamic inflammatory responses to a
physiological challenge may provide a better (more relevant,
sensitive, better interpretable) indicator of the impact of nutri-
tion on inflammatory homeostasis and thus on the control of
(acute) inflammatory responsiveness. Currently, relatively
little is known about inflammatory markers after well-
controlled acute challenges and whether these can be used
to assess the effect of nutritional interventions on acute and/
or chronic inflammation. It is also not known what exactly
constitutes an optimal inflammatory response to a challenge.
This will need to be established by comparing standardised
responses with challenges in different (sub)populations and
by exploring their predictive value in prospective cohort
studies. Despite these current gaps in knowledge, assessment
of inflammatory resilience after experimental pro-inflamma-
tory challenges is increasingly being studied. This section
describes the inflammatory challenges that have been used
to date and makes conclusions about their utility with regard
to human studies involving nutritional interventions. A range
of challenges that induce an acute inflammation was iden-
tified from the literature (Table 7). These challenges can be
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clustered according to the dominant stress triggering the
inflammatory response: metabolic stress or metabolic overload
(oral glucose load and oral lipid load); infection stress (injec-
tion of pro-inflammatory stimuli such as lipopolysaccharide
(LPS), TNF or IL-6; early response to (adjuvants in) vaccines;
or delayed-type and contact hypersensitivity responses); or
tissue damage (acute exercise or exposure to UV radiation).
Typically, the same inflammatory mediators as described pre-
viously (e.g. TNF, IL-6, CRP) have been used to follow the
dynamic inflammatory response to the different challenges
used (Table 7).
Metabolic stress
Oral glucose challenge. The oral glucose tolerance test
(OGTT) is commonly used to test for insulin resistance and
diabetes. After an overnight fast, a standardised drink contain-
ing glucose is given and subsequent blood glucose and some-
times blood insulin responses are assessed. There are some
variations in the details of the protocol used(182,183), but 75 g
(1255 kJ (300 kcal)) of glucose are typically given as a standar-
dised drink in accordance with the recommendations of the
World Health Organization (WHO)(184). The oral glucose
load induces a transient inflammatory response, which has
been assessed in several studies as levels of circulating cyto-
kines. Levels of CRP and IL-6 consistently increase, peaking
after 1 and 2–4 h, respectively(185–190). Responses of TNF
seem to be more variable. Several studies have described
increases in markers of vascular inflammation such as ICAM-
1(191), VCAM-1 and E-selectin, peaking about 2 h(186). Most
markers normalise 3–4 h after the OGTT, but responses tend
to be extended and/or stronger in obese, insulin-insensitive
and type 2 diabetic patients(190).
Oral fat challenge. Testing responsiveness to an oral chal-
lenge with fat is sometimes referred to as the oral fat tolerance
test. However, unlike the test (OFTT), this is not an established
diagnostic test with a standardised WHO-recommended proto-
col. Quality (fatty acid composition) and quantity of the fat have
differed between studies. The fat is provided as a bolus (e.g.
200–350 ml whipping cream) in some studies, whereas it is pro-
vided as a high-fat meal in other studies (e.g. 50–75 g fat as part
of a meal). Most studies have focused on the effects of the OFTT
on fatty acid handling, but the effects on markers of (vascular)
inflammation have also been described. Postprandial lipaemia
as induced by the OFTT is associated with a transient increase
in markers of (vascular) inflammation, but the size and kinetics
of these responses are quite variable between studies, undoubt-
edly due in part to the different protocols used. It has been
suggested that the responses differ between healthy individuals
and the obese as well as those with type 2 diabetes(57,192) and
are sensitive to modulation by pharmaceutical, lifestyle and
dietary interventions(185–190,193). The response has typically
been followed in terms of plasma concentrations of cytokines,
such as TNF, IL-1b, IL-6 and IL-8, soluble adhesion molecules,
such as VCAM-1 and ICAM-1, and, in some cases, circulating
levels of endotoxin over the period up to 3–6 h following the
fat challenge.
Infection stress
Challenge with endotoxin or inflammatory mediators.
Inflammatory cascades following intravenous administration
of endotoxin (bacterial endotoxin; LPS), IL-6, TNF or hydro-
cortisone have been studied in quite some detail, mainly in
the context of understanding septic shock responses. These
studies varied widely with respect to subjects, dosing and
sampling regimens used, but similar response patterns
emerge (Fig. 4) (194–198). Following intravenous administration
of LPS, there is an initial increase in TNF and IL-1 peaking
about 2 h, a rise in IL-6 reaching its maximum about 3 h,
followed by increases in IL-8 and anti-inflammatory factors
such as TNF-receptor, IL-1 receptor antagonist and IL-10 that
plateau between 3 and 6 h. However, it should be noted that
these are very invasive challenges that can only be done in
a clinical setting and their application in nutrition studies
therefore seems less feasible.
Early response to (the adjuvant component of) vaccines.
Effects of vaccination are primarily studied in relation to
enhancing vaccination efficacy and are evaluated according
to the level of protective antibody levels. However, innate
immune factors including pro-inflammatory cytokines are
induced during the (early) response to vaccination. These
early responses are probably induced by the adjuvants used
rather than by the antigen that is provided in the vaccine.
Even though early responses to vaccination have not been stu-
died extensively, several studies have indicated that enhanced
levels of pro-inflammatory cytokines can be detected in serum
post-vaccination. These studies have, however, been per-
formed in different study populations, with different vaccines
using different adjuvants (although the seasonal influenza vac-
cine has been used frequently), and serum samples have been
evaluated at different time points after vaccination, ranging
from 2 h to several weeks. Even so, in six of seven studies,
IL-6 was increased after vaccination. This occurred 2–3 h
after vaccination(199), but could also be detected after 1 or
2 d(200,201) or even after several weeks(202). In contrast, no
change in IL-6 2 weeks after vaccination was noted by
Glaser et al.(203). TNF was not increased 3 h after vaccination
in a single study(204), and CRP was increased in three vacci-
nation studies(200,201,205). Other markers that have been
described to increase after vaccination are MCP-1, eotaxin
and IL-13(206), as well as IL-2, IL-12 and IL-15(207). As noted
for other challenge models, in some studies, it was clear that
individuals with pre-existing conditions (inflammatory,
stress, depression or age-related IL-6 increase) had more pro-
minent pro-inflammatory cytokine responses than the controls
in the same studies(199–207). These findings have indicated
that pro-inflammatory cytokine levels can be measured after
vaccination; however, more studies are needed to standardise
a vaccination approach as an inflammatory challenge. Feasi-
bility is expected to be high, and the responses noted seem
quite reproducible, suggesting that most persons tested will
indeed respond by the production of pro-inflammatory
mediators. Using vaccination as an inflammatory challenge
could be relevant to identify anti-inflammatory effects of nutri-
tional intervention. An added advantage is that protective
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Table 7. Challenge models that may be used to study an inflammatory response and their features
Challenge Variability in design Affected by Effect on TNF* Effect on IL-6*
Effect on
CRP* Effect on other mediators* References
Oral glucose load Modest (dose, time points, mar-
kers)
Obesity, T2D $ to " (2–
4 h)
" (2–4 h) " (1 h) " Soluble adhesion molecules 185–190
Oral fat load High (amount and type of fat,
time points, markers)
Obesity, T2D $ to - " (6 h) $ to "
(6–8 h)
$ to " (6 h) " Soluble adhesion molecules,
chemokines, cytokines (IL-8)
185, 187,
188, 193
Acute exercise High (duration and intensity of
exercise, physical fitness,
markers)
Age, physical fitness, pre-
sence of inflammatory
disease
$ to " $ to " $ to " " Leucocytes, granulocytes 217–220,
223–226,
337
Intravenous adminis-
tration of LPS, TNF
or IL-6
High (type and dose of trigger,
subjects, time points,
markers)
" (2 h) " (2–3 h) " (24 h) " Cortisol (4 h), noradrenaline
(2 h),
fever (4 h)
300, 338, 339
UVB exposure High (type, dose and surface
area of irradiation, time points,
location)
UV dose (duration, wave-
length), skin type
$ (systemic)
" (6–12 h)
(local)
$ (systemic)
" (6–12 h)
(local)
" IL-8 (6–12 h) " IL-4, IL-10
(12–24 h), erythema, local
eicosanoids
231–234
Vaccination High (different vaccines, differ-
ent study populations, time
points)
Adjuvant used, CHD,
depression, stress,
T2D, age
$ 3 h $ to " (2 h to
several
weeks)
" (48 h) " CCL2, eotaxin, IL-13, IL-2,
IL-12, IL-15, total leucocytes,
lymphocytes and monocytes
(1 month)
199–207, 340
Skin text (DTH, con-
tact sensitisation)
High (antigens/allergens) Sensitisation, age,
exercise
No detectable
systemic
effects
Induration 214, 215
CRP, C-reactive protein; T2D, type 2 diabetes; LPS, lipopolysaccharide; CCL, chemokine (C–C motif) ligand; DTH, delayed-type hypersensitivity; ", positive association; #, negative association; $, no clear association.
* Times indicated in parentheses are the approximate times of the maximal plasma concentration of the marker.
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antibody titres can be used as a readout at a later stage so that
a single study can be used to measure two different immuno-
logical outcomes (inflammation and immune response). How-
ever, it should be noted that pre-existing elevated baseline
levels of pro-inflammatory cytokines are associated with
decreased vaccination responses(208).
Skin tests. Delayed-type hypersensitivity and contact
hypersensitivity responses to locally applied antigens or con-
tact allergens can be used to assess local inflammatory
responses triggered by the specific response to the antigen
or allergen. These responses rarely result in measurable effects
on circulating cytokines or acute-phase proteins, but instead
can be measured as local erythema or epidermal induration
24–48 h after application. As the skin is easily accessible,
local inflammation can be studied in great detail using biop-
sies. Delayed-type hypersensitivity and contact hypersensitiv-
ity responses can only be elicited in sensitised subjects
and rely on the uncontrolled history of exposure resulting
in large variation among individuals and in many non-
responders. This is key to their diagnostic value, but hampers
application as a challenge model in nutrition studies. Nonethe-
less, in the past, studies have successfully assessed the impact
of nutrition on delayed-type hypersensitivity responses using
the cell-mediated immunity multitest to simultaneously admin-
ister multiple antigens(209–211). Unfortunately, this device is no
longer available and no robust alternative methods have been
described for routine application of multiple antigens. Using a
single Candida antigen, delayed-type hypersensitivity
responses have recently been shown to be associated with a
systemic inflammatory state in older subjects (aged 60–85
years), with positive responders having significantly lower
serum CRP levels(212). To control both the sensitisation and eli-
citation phase, studies have also explored the use of exper-
imental sensitisation to an uncommon contact sensitiser,
diphenylcyclopropenone, that would not normally be
encountered(213,214). Although there are ethical considerations,
this has been successfully used to assess the effect of (exer-
cise) intervention on both the sensitisation and elicitation
phase using induration due to the local inflammation of the
skin as the readout(215).
Tissue damage
Exercise challenges. It is well established that strenuous
exercise (either an acute intensive bout or longer duration
such as marathon running) increases the concentrations of
leucocytes and neutrophils immediately following the exercise
and induces an increase in inflammatory marker concen-
trations in the bloodstream(216). However, if a challenge
model should be applicable to the general population to
assess the impact of (dietary) interventions on the elicited
inflammatory response, then a moderate exercise challenge
may be more relevant. The effects of moderate aerobic exer-
cise on pro-inflammatory cytokine production are less well
characterised than the effects of strenuous exercise as discus-
sed earlier. Most data from exercise studies relate to long-term
aerobic training (in which there is an anti-inflammatory effect)
and to strenuous exercise such as marathon running (in which
pro-inflammatory cytokines, especially IL-6, are elevated), as
discussed elsewhere(87,88). Increases in such inflammatory
cytokines after short-term exercise are much less pronounced.
The production of IL-6 increased after mild exercise in studies
performed in healthy as well as diseased adults(217–221), but
was unchanged in other studies(222,223). Whereas muscles pro-
duce the pro-inflammatory IL-6 during acute bouts of exercise;
paradoxically, IL-6 also has anti-inflammatory effects by pro-
moting the release of IL-1 receptor antagonist and IL-10(87).
This may in part explain the notion that regular, mild, low-
impact exercise has anti-inflammatory effects. The production
of TNF remained unchanged after mild exercise in healthy as
well as diseased adults in three studies(220,222,224) and
increased in another study(218). The numbers of circulating
total leucocytes, lymphocytes and monocytes increased after
mild exercise(225). Interestingly, in some studies, inflammatory
cytokines increased after moderate exercise in patients, but
not in control subjects. Rabinovich et al.(223) described that
serum TNF increased in patients with cystic fibrosis after mod-
erate exercise but not in controls. Likewise, IL-6 increased
after mild exercise in cystic fibrosis patients, but not in healthy
controls in another study(224). The effect of mild exercise on
CRP was only tested in a single study, and was found to be
increased in patients with coronary artery disease but not in
control subjects(219). Similar findings have been seen in studies
with children(226).
UV irradiation. Whole-body exposure to high doses of
sunlight or UVB radiation causing sunburn increases the
levels of inflammatory mediators in the circulation. Milder or
more focused exposure to UVB radiation was shown to
decrease the skin contact hypersensitivity response(214) as
well as some systemic responses such as natural killer cell
activity(214,227) and ex vivo production of cytokines(228). How-
ever, circulating cytokine levels after single exposure to UVB
were not affected(229,230) and even after 10 d of repeated
exposure, only IL-8 and TNF were marginally increased(230).
It is therefore unlikely that a practically feasible UV challenge
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Fig. 4. The time course of plasma cytokine concentrations after an inflamma-
tory challenge (in this case a bolus intravenous injection of Escherichia coli
lipopolysaccharide (LPS)). Concentrations and time are shown on arbitrary
scales. There is an initial appearance of inflammatory cytokines (TNF and
IL-1), followed by IL-6, and then anti-inflammatory cytokines (TNF receptor
(TNFR), IL-1 receptor antagonist (IL-1ra) and IL-10). Reproduced from
Bentham Science Publishers(300) with permission.
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can be developed that can be used to assess indicators of
inflammation systemically. However, using microdialysis
and/or punch biopsies, pro- and anti-inflammatory responses
can be sequentially assessed in the skin in the hours to
days following a single dose of two or three minimal
erythemal doses of UVB radiation(231–233). This is a useful
model to assess local mediators including short-lived eicosa-
noids involved in the initiation and resolution phase of
UVB-induced skin inflammation(234).
General comments on challenge models
CRP, TNF and IL-6 are the most commonly measured inflamma-
tory markers after the various challenges, although other cyto-
kines, chemokines, adhesion molecules and leucocyte
numbers have also been used. For challenges that induce
inflammation in the skin, local markers such as swelling,
erythema, cellular infiltrate and local levels of mediators in exu-
date from (suction) blisters or biopsies have also been used.
Steady-state differences in inflammatory markers between
patients with diseases with an inflammatory component and
healthy people seem to be more consistent than differences in
post-challenge responses. However, stronger or more extended
inflammatory responses (IL-6, TNF and CRP) to challenges in
patients v. controls have also been noted in several studies.
Challenges other than with glucose are not, or are poorly, stan-
dardised and differ greatly between studies with respect to the
challenge (amount and quality of fats, type and duration of exer-
cise, wavelength and energy intensity of UV radiation, and type
of vaccine), markers measured, time points measured and the
way in which results are analysed. In most studies, the inflam-
matory response is assessed at one or more arbitrary time
points after the triggering challenge, few studies have followed
the detailed kinetics of the responses, few included a proper
time control for circadian rhythms and very few have integrated
the entire response, for instance, by analysing the AUC(197).
Different challenges have been used in different contexts,
using different sets of readouts and different (subject or patient)
populations. This makes it complex to compare the challenges
based on available data. A recent study observed that multiple
intermediates of the glutathione synthesis pathway showed
time-dependent suppression in response to the OGTT in over-
weight subjects(235). These metabolic perturbations were subtle
and were only observed using metabolic profiling at multiple
time points following a physiological challenge (OGTT). This
is a good example of more sophisticated integrative analysis,
which may also be very useful for the detailed analysis of the
kinetics of complex inflammatory responses(235).
It would be very useful to have reliable kinetic data of the
inflammatory responses following well-selected, standardised
pro-inflammatory challenges. These could then serve as a
starting point for systematic comparisons of the kinetic profiles
in different subpopulations (obese, insulin insensitive, dia-
betic, older individuals, etc.) and for careful evaluations of
the impact of (dietary) interventions on the resilience of
these responses. The established kinetic responses following
an intravenous LPS challenge could serve as a useful point of
reference for this (see Fig. 4). However, care should be taken
not to introduce artifacts due to the sampling as several studies
have demonstrated that the mere presence of an indwelling
catheter results in the continued local elevation of IL-6 levels
compared with samples taken from the contralateral arm
using repeated venepuncture(236–238).
Although it may not yet be possible with the relatively limited
dataset available, it would be very useful to work towards stan-
dardised challenges combined with standardised sampling and
analytical regimens and standardised data analyses, and use
these as an integrated biomarker of inflammatory resilience.
This resembles what has been done with the OGTT for the
assessment of insulin resistance and diabetes and would facili-
tate comparison between studies in prospective cohorts,
which is needed to establish the predictive value and clinical rel-
evance of resilience to (acute) inflammatory challenges.
Conceptually, the use of standardised challenges is an inter-
esting approach and there are some indications that resilience
of dynamic inflammatory responses may have added value
over assessing markers during steady state only. However,
there are too few data to draw firm conclusions at this
point. Some studies have indicated different post-challenge
inflammatory responses in patient populations, but it is not
yet feasible to define healthy inflammatory responsiveness to
a particular challenge based on the available published data.
Oral glucose and fat challenges and potentially the early
response to a vaccine seem to be best standardised, most rel-
evant and most feasible challenges for application in nutrition
studies and for inclusion in prospective cohort studies.
Key messages
(1) Inflammatory responsiveness or resilience to challenges
may provide a more sensitive and meaningful indication
of inflammatory state in the general population than the
assessment of markers during steady state.
(2) There is a need to standardise challenge(s) and assessment of
the subsequent inflammatory response, including multiple
sampling points to assess the kinetics of the response. As
many inflammatory markers also have a circadian rhythm,
such studies should involve proper time controls.
(3) There is a need to firmly establish whether standardised
assessment of the dynamic response to an (acute)
inflammatory challenge does indeed add value (clinical
relevance, sensitivity, relevance, interpretability, etc.) com-
pared with assessment of inflammatory markers during
the steady state.
(4) It is likely that a combination of multiple inflammatory
markers (perhaps the same as those used to assess
inflammation in the steady state) and integrated readouts
based upon kinetic analysis following defined inflamma-
tory challenges will be most informative.
Emerging markers of inflammation
Expression of cell surface markers
New technologies allow the profiling of hundreds of cell
surface markers in peripheral blood and tissues, and the
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identification of surface markers whose extent of expression
correlates with the inflammatory status. Recent studies have
suggested that surface expression of CD11b on granulocytes
is a marker of granulocyte activation; its expression is
increased in obesity(239). Weight loss in obese subjects and
in individuals with diabetes is associated with decreased
expression of CD11b on granulocytes and of CD66b on mono-
cytes(239). CD11c, a b2 integrin expressed on monocytes,
plays an important role in monocyte adhesion to inflamed
endothelial cells. Obese human subjects with the metabolic
syndrome have higher CD11c levels on monocytes than lean
healthy controls(240), suggesting that these monocytes are
involved in the inflammatory process of atherosclerosis.
For these biomarkers, little information is available on
the impact of confounders, such as smoking or physical
(in)activity.
Clusters of markers
An important approach to ascertaining the clinical relevance
of selected biomarkers of inflammation is to perform longi-
tudinal studies following human subjects over time(241). Sev-
eral such longitudinal studies in human subjects have sought
to identify biomarkers of morbidity and mortality, with mor-
tality as the most ‘robust clinical endpoint’. Inflammatory fac-
tors such as CRP, TNF and IL-6 have repeatedly been found to
associate with increased mortality and frailty, but mostly in
cross-sectional studies(242,243). Moreover, analyses of associ-
ations with single factors in either cross-sectional or longitudi-
nal studies are usually weak or not always reproduced in
different populations. A major challenge in studies of long-
lived species like humans is clearly logistics of long-term
follow-up. An approach to this was made in the Swedish
immune longitudinal studies including octo- and nonagenar-
ians (OCTO/NONA) studies, taken here as an example,
which examined soluble and cellular markers at baseline in
85-year-old subjects to seek predictive biomarkers for mor-
tality in cohorts with high mortality over reasonable follow-
up times(244,245). The rationale was to identify those predictive
biomarkers with potential applicability to other, younger,
populations. These studies not only performed follow-up at
2, 4 and 6 years, but also resampled, so that changes to bio-
markers over time could be assessed. It was found that
single markers were relatively uninformative, as expected
from the above considerations, but that clusters of markers
were significantly associated with mortality. Thus, a cluster
of cellular markers including an inverted CD4:CD8 ratio due
to an accumulation of CD8þ late-stage memory cells and infec-
tion with the common herpes virus cytomegalovirus, now
thought to drive this ‘memory inflation’, were significantly
associated with mortality. Cytomegalovirus infection has a
pro-inflammatory action, increasing the levels of cytokines
such as interferon-g. The OCTO/NONA studies also identified
a second cluster of soluble factors comprising increased IL-6,
CRP and the thyroid hormone and vitamin A transport protein
transthyretin, which correlated with cognitive impairment and
independently associated with mortality. Individuals with
neither risk cluster had better survival at follow-up than
those with either one or the other risk cluster, and people sim-
ultaneously with both risk clusters had the worst survival(244).
These findings emphasise that multiple inflammatory factors
need to be assessed in combination. The importance of the
balance between pro- and anti-inflammatory factors was
emphasised by the finding that although the majority of sub-
jects in this risk group were already deceased at 2- and
4-year follow-up, a minority exited the risk group and
remained alive at this time. These rare individuals were
characterised by high plasma IL-10 levels, as well as retaining
high IL-6 levels(245). This risk cluster remains an emerging
marker because, as defined thus far, it has limitations that
require further study applying more sophisticated method-
ology to well-characterised cohorts. These limitations include,
but are not limited to, the following: the cluster has only been
shown to be relevant in a small study in one very old popu-
lation in one country; it lacks the sophistication of modern
immune analysis; it is unknown at which calendar age it
becomes relevant; associations with cause of death are
unknown and associations with underlying disease states are
also unknown; finally, it does not take nutrition, psychological
stress or pathogen environment into account. Given that nutri-
ents and dietary patterns may influence the components of the
clusters described above(1,6), it is likely that the clusters them-
selves may be targets for nutritional interventions.
Stress markers
The adverse tissue environment of immune-mediated and
metabolic disease triggers a cellular stress programme in
response to hypoxia, inflammation, reactive oxygen species
as well as the lack or imbalanced presence of nutrients(246).
Specific metabolic and functional processes occur in
specialised cellular organelles such as the ER, peroxisomes
and mitochondria(247). The unfolded protein response (UPR)
is a well-conserved mechanism of these organelles to restore
cellular homeostasis in response to stress; however, unre-
solved or chronic activation of UPR pathways induces inflam-
matory mechanisms or cell death. Even though they are
phenotypically different, the diseases described in Table 4
share similarities of the cell stress response at the molecular
level(248). Hypoxia and inflammatory signals as well as meta-
bolic challenges increase cellular energy requirements and
reactive oxygen species production and have a negative
impact on protein folding machinery of the cell. Consistently,
interference with ER(249–251) and mitochondrial UPR-associated
signalling pathways(252–254) has been shown to have an
impact on disease susceptibility and pathological outcome in
various animal models. Generally accepted surrogate
markers for UPR include cellular expression and secretion of
compartment-specific chaperones (CPN) such as glucose-
related protein (GRP) 78 and heat shock protein (HSP) 78
CPN60, the latter representing the main CPN involved in
protein folding in the mitochondria, since induction of
these proteins is a main purpose of UPR signalling(255,256).
Increased protein and mRNA expression levels of GRP78 in
human mononuclear cells were shown to be associated with
deregulated blood glucose homeostasis, increased levels of
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inflammatory cytokines and the metabolic syndrome, demon-
strating clinical relevance for ER-UPR markers in human
disease(257). In addition, plasma HSP60 levels were associated
with hypertension and increased risk for CVD(258,259). To
evaluate ER-derived signalling leading to altered gene
expression, splicing of X-box binding protein 1 (Xbp-1)
mRNA is commonly monitored. The spliced mRNA encodes
an active, UPR-associated transcription factor, spliced X-box
binding protein 1 (sXBP-1), and splicing of Xbp-1 mRNA rep-
resents an early event during ER-UPR(251,255). Induction of
GRP78 or CPN60 is mostly measured by Western blot analysis,
immunohistochemical analysis and quantitative polymerase
chain reaction (PCR), whereas Xbp-1 mRNA splicing is detec-
ted by using specific primers for Xbp-1 mRNA or sXbp-1
mRNA for quantitative PCR analysis. In conclusion, GRP78
and HSP60 represent surrogate markers for chronic conditions
with inflammatory pathologies that can be measured in biop-
sies from the disease-relevant tissue or in specifically isolated
target cells as well as circulating protein in plasma(248). These
could be tested as potential early markers for the onset of
inflammation, where data are not yet available, including
evaluating the potential for modulation by interventions.
MicroRNA
MicroRNA (miRNA) are short (average twenty-two nucleo-
tides) non-coding ribonucleic acids that have been found in
eukaryotic cells. They have important regulatory functions
by controlling gene expression, by inhibiting protein trans-
lation and by inducing target mRNA destabilisation(260).
miRNA can be detected by PCR, specific microarrays or,
more comprehensively, by next-generation sequencing
approaches(261). Endogenous circulating miRNA in human
plasma are potential candidates as stable biomarkers for
health status, organ dysfunction and disease(262–264). As
many of the common diseases have an inflammatory com-
ponent that may be regulated by non-coding RNA(265), it is
expected that plasma miRNA profiling will reveal sensitive
biomarkers for the onset or modulation of chronic
inflammation in humans(262,266–268). The latter could include
nutritional modulation.
Microbiota and associated markers
As discussed earlier, microbiota and, particularly, gut micro-
biota might play an important role in human health and
physiopathology. It is possible that circulating traces of trans-
located bacteria or bacterial components could be used as
biomarkers to predict metabolic disease risk in humans.
Measurements of blood LPS have frequently been reported
in the literature as a feature of mucosal barrier failure. How-
ever, such measures are rather unspecific, are limited to
Gram-negative organisms and pose some technical difficulties.
Alternative methods to detect material of bacterial origin or to
detect responses to specific organisms are emerging. Indeed, a
battery of antibodies against different bacterial antigens is
currently under investigation, although their physiological
role is still unclear. However, this approach may provide
new markers of inflammation. For instance, an array of immu-
nohistological tools have been developed to study, diagnose
and/or score ulcerative colitis and Crohn’s disease(269,270).
So far, the combination of perinuclear anti-neutrophil
cytoplasmic antibodies (P-ANCA) and anti-Saccharomyces
cerevisiae antibodies (ASCA) seems to be the best serological
test to distinguish ulcerative colitis (P-ANCAþ and ASCA2/low)
from Crohn’s disease (P-ANCA2/low and ASCAþ)(269). The
usefulness of such tools in the generally healthy population
needs further development. In addition, specific bacterial
16S ribosomal DNA detection by PCR amplification in blood
is a tool being used more frequently(271–273). The combination
of excellent sensitivity and specificity, ease and speed has
made real-time PCR technology an appealing alternative to
conventional culture-based testing methods. This approach
has been used recently to show a positive association between
16S ribosomal DNA in blood and diabetes onset(274). The 16S
ribosomal DNA concentration was analysed in blood in a
cohort of 3280 subjects without diabetes or obesity. Baseline
16S ribosomal DNA level was higher in those subjects who
developed diabetes by the 9-year follow-up(274).
Key messages
(1) Altered expression of activation markers on the sur-
face of circulating leucocytes may be biomarkers of
inflammation.
(2) Longitudinal studies of the very old suggest that a profile
of plasma inflammatory markers correlates with altered
risk of mortality and is more predictive than any marker
alone.
(3) UPR are the consequence of sustained cellular stress in
the context of immune-mediated or metabolically driven
chronic pathologies with GRP78 and CPN60 as surrogate
markers.
(4) Endogenous circulating miRNA are quite stable potential
biomarkers for health status and organ dysfunctions, and
may reveal very sensitive information about inflammatory
state.
(5) There are emerging approaches to assess the microbiota
and the translocation of micro-organisms.
(6) These emerging markers of inflammation may be influ-
enced by nutrition and represent potential novel targets
for nutritional interventions.
Emerging technologies
Applications of omic technologies to identify new markers
and to monitor the effect of interventions
Genomics was originally described as the comprehensive
analysis of the genome of an organism that includes efforts
to determine the entire DNA sequence and fine-scale genetic
mapping. A broader definition than this may also be
used(275), according to which ‘genomics’ is the study of all
of the genes of a cell, or tissue, at the DNA (epigenome,
genome), mRNA (transcriptome) and protein (proteome)
levels. New high-throughput technologies such transcriptomics,
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proteomics and metabolomics have created unprecedented
opportunities for a less biased and more comprehensive assess-
ment of even subtle phenotypic changes. To integrate appli-
cations of these technologies more efficiently into nutrition
research, nutrigenomics has been initiated as a new innovative
research strategy about 10 years ago when the working draft
of the human genome was announced(276–280). In addition
to comprehensive phenotyping, nutrigenomics includes
innovative combinations of molecular nutrition research and
genomics applications. It allows the comprehensive study of
diverse tissue andorgan-specific gene expression patterns (tran-
scriptome), organisation and modification of the chromatin
structure (epigenome), protein expression patterns including
post-translational modifications (proteome) as well as metab-
olite profiles (metabolome)(279,281). To achieve the powerful
integrationof all different nutrigenomic andphenotypedata sys-
tems, biology strategies are being developed. Nutritional sys-
tems biology is a holistic approach merging various omics data
(e.g. genome, epigenome, metabolome, proteome, micro-
biome) from individual organs andbody compartments at differ-
ent time points of a nutritional intervention with the use of
computational methods and predictive mathematical models.
This requires a large degree of standardisation, multidisciplinary
collaboration, improved bioinformatics and statistical methods
and sophisticated and partly Web-based databases such as the
Nutritional Phenotype database(282,283).
It is becoming evident from recent studies that nutrige-
nomics is promoting an increased understanding of how a
nutritional intervention mechanistically influences metabolic
pathways and homeostatic control. Furthermore, it reveals
how this regulation is disturbed during development of
diseases, and the extent to which individual sensitising geno-
types contribute to such diseases by allowing comprehensive
phenotyping and the identification of early biomarkers for
pre-disease states. A few recent nutrigenomics-based appli-
cations related to systemic and organ-related pro-inflamma-
tory states are discussed here. Nutrigenomics studies using
appropriate mouse models are essential to better understand
the systems-wide changes of a metabolically healthy to a
less healthy organism and to identify potential early bio-
markers that can then be validated in human studies(284–286).
Recent studies have already shown the great opportunities
of this new research area(191,287,288).
Whole genome transcriptome analysis has been used to
demonstrate that intake of n-3 fatty acids by healthy older per-
sons for 26 weeks can alter the gene expression profiles of per-
ipheral blood mononuclear cells, as a ‘surrogate’ biomarker for
whole-body health status, to a more anti-inflammatory and anti-
atherogenic status, although CRP was not changed(289). Path-
way analyses revealed significantly decreased expression of
genes involved in inflammatory pathways, such as eicosanoid
synthesis, cytokine signalling and mitogen-activated protein
kinase signalling, and in pathways related to atherosclerotic
processes, such as cell adhesion and scavenger receptor
activity(289). A combination of peripheral blood mononuclear
cells and adipose tissue transcriptome, plasma protein analysis
and plasma and urine metabolomics was used to study the
effects of specific dietary components to reduce low-grade
inflammation as well as metabolic and oxidative stress in
healthy overweight men with mildly elevated plasma CRP
levels(290). Whereas CRP levels were again found to be
unchanged, a multitude of subtle changes were detected by
an integrated analysis of nutrigenomics datasets, which indi-
cated modulated inflammation of adipose tissue, improved
endothelial function, altered oxidative stress and increased
liver fatty acid oxidation. Another nutrigenomics study
investigated the effect of saturated and monounsaturated fat-
rich diets on insulin sensitivity, serum lipids and gene
expression profiles of adipose tissue in subjects at risk of the
metabolic syndrome(291). Consumption of the saturated fat-
rich diet resulted in the up-regulation of processes related to
inflammation. Several genes linked to inflammation included
markers for recruitment of leucocytes, genes involved in eicosa-
noid synthesis and monocyte/macrophage markers. The mono-
unsaturated fat-rich diet led to a more anti-inflammatory gene
expression profile and resulted in a down-regulation of several
adipose tissue macrophage genes. This study showed that
subtle organ-specific changes in phenotypic profiles could be
detected with genomics methods, which is very relevant to dis-
criminate between early organ-related changes and late sys-
temic changes in (pro-)inflammatory and less healthy status.
In a more recent study, a large set of plasma proteins related
to chronic diseases, inflammation, endothelial function and
metabolic signalling was assessed in a population of relatively
healthy, middle-aged, overweight subjects(291,292). Clusters of
proteins associated with BMI or insulin were identified.
Leptin and a number of pro-inflammatory proteins, previously
identified as possible biomarkers for obesity-related disease
(e.g. C3, CRP, serum amyloid P, vascular endothelial growth
factor), clustered together and were positively associated
with BMI and insulin. IL-3 and IL-13 clustered together with
apoA1 and were inversely associated with BMI, and might
be potential new biomarkers. These plasma protein clusters
could have potential applications for improved phenotypic
characterisation of subjects in nutritional intervention studies
or as biomarkers in the early detection of obesity-linked dis-
ease development and progression.
As the recent developments in using nutrigenomics for
metabolic profiling and characterising complex interactions
are looking very promising, future studies have to link these
results to accepted functional outcome measures. Application
of metabolic perturbations in combination with comprehen-
sive nutrigenomics-based phenotyping will improve the diag-
nostic sensitivity and ultimately allow discriminating between
healthy, less healthy and unhealthy people(181,235,293).
Non-invasive imaging
Recent developments in non-invasive molecular imaging
(such as magnetic resonance imaging) are allowing quantifi-
cation of physiological changes in vivo using specific
probes. Nanoprobes can be used to image specific cells and
tissues within a whole organism, at the moment mainly in
animal models such as mice(294). Intravital fluorescence
microscopy in mice is beginning to provide quantitative and
dynamic insights into cell biology and immunology(295).
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Recent application of specific mass spectrometry techniques in
combination with magnetic resonance imaging has provided a
systems biology approach to study inflammation in mice(296).
In a recent study, novel microscopy techniques have been
used to characterise the composition of visceral adipose tis-
sues of lean and obese mice including adipocytes, macro-
phages and collagen fibrils in a label-free manner, allowing
dynamical monitoring of lipid metabolism-related processes
relevant for immunometabolism(297). Finally, non-invasive
imaging has been applied in mouse models of inflammatory
disease and for imaging of macrophages in vivo by using acti-
vatable fluorescent probes, radiolabelled inhibitors and nano-
particles(298). Increasingly, these imaging techniques are also
discussed for their potential to identify subclinical athero-
sclerosis in humans(299). The goals for the years to come
must include translation of the experimental work to visualisa-
tion of biological targets relevant for local organ-related and
systemic inflammatory states in humans.
Key messages
(1) Applications of metabolic perturbations in combination
with comprehensive nutrigenomics-based phenotyping
will significantly improve the diagnostic sensitivity, allow-
ing discrimination between healthy, less healthy and
unhealthy people.
(2) For predictive mathematical modelling of the modulation
of inflammatory states by nutritional interventions, the
integration of different nutrigenomics and phenotype
data from individual organs and body compartments
has to be achieved by nutritional systems biology
approaches.
(3) A range of imaging techniques is emerging that have the
potential to non-invasively identify inflammation and its
consequences.
Summary, conclusions, identification of key gaps, overall
recommendations and overall key messages
There is an urgent necessity for reliably monitoring inflamma-
tory status in the context of disease and interventions to pre-
vent or treat disease, including dietary modification.
Currently, guidelines on how to accurately assess inflam-
mation are lacking. To monitor inflammation in a meaningful
way, the markers used must be valid; that is, they must reflect
the inflammatory process under study and they must be pre-
dictive of future health status. Inflammation per se is a
normal, essential, complex physiological process crucial for
restoring and maintaining health. This process involves
many cells and mediators. The latter include numerous pep-
tides and proteins that circulate in the bloodstream (e.g. cyto-
kines, chemokines, soluble forms of adhesion molecules and
acute-phase proteins). These are involved in, or produced as
a result of, the inflammatory process irrespective of its trigger
and its location. Thus, they are common to all inflammatory
diseases, to acute and chronic inflammatory responses and
to both high-grade and low-grade inflammation. They would
be considered as general markers of inflammation, with no
specificity with regard to the trigger or the site of inflammatory
activity. Furthermore, many of these soluble markers are pre-
sent at readily detectable concentrations in the bloodstream of
healthy individuals, although it is not always clear what their
role in healthy persons might be. In contrast, there are inflam-
matory markers specific to inflammatory disease, which
cannot usually be measured, or are present at very low con-
centrations, in healthy individuals. The focus in inflammation
research has been very much on such pro-inflammatory mar-
kers that are part of an amplification cascade or that cause
tissue damage, and the factors that influence these and
which can be used to distinguish disease. There has been
less emphasis on anti-inflammatory markers, which include
receptor antagonists, soluble forms of receptors, cytokines
and lipid mediators that act to down-regulate the production
of inflammatory mediators. There is even less understanding
of those factors that terminate (resolve) inflammation. Cur-
rently, there is no consensus on which markers of inflam-
mation best represent low-grade inflammation or can
differentiate between acute and chronic inflammation or
among the initiation, propagation and resolution phases of
inflammatory responses. For most inflammatory markers,
there is limited information on the predictive value of (differ-
ences in or changes in) their concentration from prospective
studies; that is, information on their role as (independent)
markers of disease risk and outcome is largely lacking. Many
modifying factors affect the concentration of an inflammatory
marker at a given time; the effects of some factors, such as age,
physical (in)activity and smoking, on a small number of
inflammatory markers are well described, but the effects of
these factors on the range of markers considered here are
mostly not known. In particular, knowledge of the effects of
genotype, sex and gut microbiota is limited. In addition,
those modifying factors for which there are relatively few
data (e.g. genotype) may have a larger effect on inflammatory
responses than factors for which there are larger amounts of
data available. Measuring the concentration of inflammatory
markers in the bloodstream under basal conditions (e.g. in
fasted blood in the early morning) is probably not as informa-
tive as data related to the concentration change in response to
a challenge. In the literature, a number of challenges reflecting
metabolic stress, infection and tissue damage have been
described. However, many of these challenges are poorly
standardised, and the nature of the dynamic of the response,
the markers influenced (or not), the extent of variation in
the response among individuals and the effect of modifiers
on the response are currently not well documented. Efforts
to standardise pro-inflammatory challenge tests to assess the
resilience of inflammatory control are urgently needed. Most
intervention studies focus on a single marker, or on a small
number of markers, of inflammation. There are few attempts
to define composite markers that may be more specific or pre-
dictive. Patterns and clusters may be more robust biomarkers
of inflammatory state and inflammatory response than individ-
ual or small numbers of markers. Therefore, it is likely that a
combination of multiple inflammatory markers (perhaps the
same as those used to assess inflammation in the steady
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state) and integrated readouts based on kinetic analysis fol-
lowing defined challenges will be the most informative bio-
marker of inflammation. New techniques are emerging to
monitor inflammation but these are, in general, at the early
experimental stages and have had little translation to humans.
There will be a need to fully validate these technologies.
Overall key messages
(1) Acute inflammation is a normal physiological response
crucial for maintaining homeostatic control, but when it
becomes chronic, inflammation contributes to the patho-
physiology of a range of diseases.
(2) Common soluble markers of inflammation include cyto-
kines, chemokines, lipids, acute-phase proteins and
adhesion molecules and common blood cellular markers
of inflammation include various subclasses of leucocytes.
(3) The same markers are involved in both acute and chronic
inflammatory processes, meaning that the markers them-
selves, in isolation, cannot be used to distinguish the two
processes.
(4) There are a number of endogenous and exogenous modi-
fiers that influence the levels of inflammatory markers
resulting in significant between-individual variation.
These modifiers include age, body fatness, physical
(in)activity, sex, genotype, smoking habits, diet, the com-
position of the gut microbiota and the use of certain
medications.
(5) Inflammatory responsiveness or resilience to challenges
may provide a more sensitive and meaningful indication
of inflammatory state in the general population than the
assessment of markers during the steady state.
(6) There is a need to standardise pro-inflammatory chal-
lenge(s) and assessment of the subsequent inflammatory
response.
(7) It is likely that a combination of multiple inflammatory
markers (perhaps the same as those used to assess
inflammation in the steady state) and integrated readouts
based on kinetic analysis following defined challenges
will be the most informative biomarker of inflammation.
(8) A number of novel markers of inflammation are emerging
but these require further exploration and validation.
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